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3SUMMARY
Evidence from clinical and animal studies indicates an 
interaction between cancer and the haemostatic system. 
Human malignancy disrupts the normal haemostatic 
balance in favour of a hypercoagulable state while 
studies on the effects of anticoagulant/antiplatelet 
agents in animal models of metastasis indicate a role 
for coagulation in the metastatic process. Recent work 
has demonstrated that Streptokinase inhibits pulmonary 
tumour seeding in an animal model of metastasising 
breast carcinoma. The purpose of the first half of this 
thesis was to investigate the mechanism of pulmonary 
tumour inhibition by Streptokinase. Validation of the 
experimental tumour model was first performed to 
confirm the dose, time of administration and effect of 
Streptokinase on pulmonary tumour seeding. The results 
of these experiments confirmed that the inhibitory 
effect of Streptokinase on pulmonary tumour nodule 
formation was reproducible.
It was hypothesised that the effect of tumour 
inhibition by Streptokinase was secondary to 
dissolution of the fibrin clot surrounding tumour cells 
entrapped within the pulmonary microcirculation. In 
order to confirm fibrin clot lysis, a study was 
undertaken to measure fibrinolytic activity during 
Streptokinase treatment by estimation of plasma fibrin 
degradation product levels (FDP). The results showed a 
tendency to increased FDP levels in animals receiving
4Streptokinase although this failed to reach statistical 
significance possibly due to the low level fibrinolytic 
activity exhibited by untreated controls.
In order to provide conclusive evidence that the 
antitumour effect of Streptokinase was due to fibrin 
clot breakdown, a further study was performed to 
compare the effect of Streptokinase and a second 
fibrinolytic agent, human recombinant tissue 
Plasminogen Activator (rt-PA), on pulmonary tumour 
seeding. The results showed a comparable twofold 
reduction in pulmonary tumour seeding by both these 
fibrinolytic agents. The demonstration that two 
structurally distinct compounds, unrelated except for 
their ability to induce fibrin clot lysis, produce a 
similar antitumour effect, suggests that this effect is 
likely to be secondary to fibrin clot lysis.
Platelets are also an integral component of 
thrombi surrounding tumour cells arrested in the 
microvasculature. Further animal studies were therefore 
performed to establish whether a dual assault on fibrin 
clot formation and platelet deposition had an additive 
inhibitory effect on pulmonary tumour seeding. Since 
tumour cell-induced platelet activation may occur via a 
number of pathways including the generation of thrombin 
and activation by ADP, this study used two anti­
platelet agents with separate mechanisms of action. 
Although there was a trend towards inhibition of 
pulmonary tumour seeding with aspirin, this failed to 
reach a significant level suggesting that platelet
5activation by the Mtln3 cell line may be independent of 
the cyclo-oxygenase pathway. In contrast, ticlopidine 
significantly inhibited pulmonary tumour seeding 
suggesting that tumour cell-induced platelet 
aggregation by the Mtln3 cell line may be dependent on 
the generation of ADP. The combination of ticlopidine 
and Streptokinase on inhibition of pulmonary tumour 
seeding was no more effective than Streptokinase 
treatment alone indicating that in this animal model, 
fibrin may play a more important role than platelets in 
the intravascular phase of the metastatic process. 
These animal studies suggest that fibrinolytic therapy 
may have a role in reducing metastatic progression in 
patients with malignant disease.
The second half of this thesis was designed to 
identify cancer patients who might benefit from such 
antimetastatic therapy. Animal studies have 
demonstrated that manipulation of a primary tumour 
facilitates tumour cell dissemination via the 
bloodstream and may promote metastasis. Surgery and 
anaesthesia may further enhance the metastatic 
potential of circulating tumour cells shed during 
operative manipulation by inducing a state of relative 
immune suppression and facilitating tumour cell seeding 
in target organs in a more fertile, hypercoagulable 
blood environment. Fibrinolytic therapy is most likely 
to be effective if administered during such tumour cell 
dissemination. The studies of Turnbull using the "no­
touch" isolation technique in patients with colon
6cancer have provided the only clinical evidence that 
surgical manipulation of primary tumours may facilitate 
metastasis. Evidence of intra-operative tumour cell 
dissemination might indicate a role for peri-operative 
antimetastatic therapy. It was therefore hypothesised 
that surgical manipulation during resection of a 
primary malignant tumour enhanced metastasis by 
facilitating tumour cell shedding into the bloodstream. 
Initial studies using two colour flow cytometry to 
detect circulating tumour cells in patients with breast 
cancer during surgery were unsuccessful due to 
inadequate sensitivity at low tumour cell 
concentrations. Further studies used reverse
transcriptase PCR to amplify two genes encoding 
structural epithelial proteins, cytokeratin 18 and the 
breast carcinoma-associated antigen DF3. The absence of 
epithelial cells in normal peripheral blood suggested
that these genes might be suitable targets for the
detection of circulating malignant breast epithelium. 
Our initial results however demonstrated expression of 
the cytokeratin 18 gene in the peripheral blood of 
healthy volunteers possibly due to low level 
transcription of the CK 18 gene in non-epithelial
tissues. In contrast, DF3 was consistently expressed in 
cells derived from primary malignant breast carcinomas 
but was absent in all normal peripheral blood samples. 
An assessment of sensitivity demonstrated that reverse 
transcriptase PCR could detect 10 tumour cells per 5 ml 
of blood. A preliminary clinical study of nine patients
7undergoing surgery for primary breast carcinoma 
demonstrated the presence of DF3 in the blood of one 
patient pre-operatively and four patients during 
surgery. DF3 was absent in all post-operative samples 
and in all samples obtained from patients undergoing 
surgery for benign disease. The presence of DF3 in 
patients undergoing surgery for malignant disease but 
not benign disease suggests that this represents 
circulating malignant epithelial cells. Furthermore, 
the presence of DF3 in four of nine patients during 
surgery suggests that surgical manipulation of 
malignant breast tumours may enhance haematogenous 
tumour cell dissemination. These findings suggest that 
antimetastatic therapy may have a role in patients 
undergoing surgery for malignancy.
CONTENTS
PRELIMINARY MATERIAL
List of Tables and Illustrations 
List of Abbreviations 
Acknowledgement s 
Declaration
INTRODUCTION
1.) THE MECHANISM OF DEVELOPMENT OF METASTATIC 
DISEASE
1.1 Pathogenesis of metastasis
1.2 Metastatic heterogeneity of malignant 
neoplasms
2.) THE HAEMOSTATIC SYSTEM
2.1 Vascular endothelium
2.2 Platelets - structure and function
2.3 Coagulation pathway
2.4 Fibrinolytic pathway
3.) CANCER AND COAGULATION
3.1 Clinical evidence for altered coagulation 
in cancer
3.2 Laboratory evidence for altered coagulation 
in cancer
3.3 Role of fibrin and the fibrinolytic system 
in malignant disease
3.4 Tumour procoagulant activity
3.5 Role of platelets
3.6 Clinical application of anticoagulant and 
antiplatelet therapy
3.7 Summary and role of future studies
3.8 Clinical application of fibrinolytic 
therapy
4.) SURGERY AND METASTASIS
4.1 Evidence for tumour cell dissemination by 
surgical trauma
4.2 Role of surgical stress
4.3 Summary and statement of hypothesis
PAGE
17
24
26
29
33
36
39
40
42
45
48
52
54
58
59
63
65
9CHAPTER 1
Validation of previous work and animal 
model of metastasis
Introduction 69
Studies to validate previous work 73
Results 74
Discussion 77
CHAPTER 2
Studies to determine whether inhibition 
of pulmonary tumour seeding by Streptokinase 
is associated with fibrin clot lysis
Introduction 83
Materials and methods 84
Experiment 87
Results 87
Discussion 89
CHAPTER 3
Inhibition of pulmonary tumour seeding 
by fibrinolytic therapy: A comparison 
of Streptokinase and human recombinant 
tissue plasminogen activator
Introduction 91
In vitro assessment of cytotoxicity 92
Experiment 96
Results 99
Discussion 99
CHAPTER 4
Studies to determine whether pulmonary 
tumour inhibition by fibrinolysis 
is enhanced by antiplatelet therapy
Introduction 104
In vitro assessment of cytotoxicity 106
Experiment 1 109
Experiment 2 112
Discussion 115
10
CHAPTER 5
Flow cytometric detection of tumour cells 
in blood
Introduction 120
Preliminary experiments
- one colour flow cytometric analysis 131
- two colour flow cytometric analysis 137
Patient study 141
Discussion 144
CHAPTER 6
Reverse transcriptase and polymerase 
chain reaction to detect circulating 
tumour cells in peripheral blood
Introduction 149
Preliminary experiments
- Assessment of specificity 156
- Assessment of sensitivity 163
Patient study 166
Discussion 172
FINAL DISCUSSION 17 6
REFERENCES 186
11
LIST OF TABLES AND ILLUSTRATIONS
Tables: PAGE
1 Validation of Wexler's method 76
2 Effect of intravenous Streptokinase 86
on FDP levels
3 Effect of rt-PA and Streptokinase 97
on tumour cells: Clonogenic assay
4 Effect of rt-PA and Streptokinase 97
on tumour cells: MTT assay
5 Effect of aspirin and ticlopidine 108
on tumour cells: Clonogenic assay
6 Effect of aspirin and ticlopidine 108
on tumour cells: MTT assay
7 Efficiency of tumour cell recovery 142
from blood by two colour flow
cytometric analysis
8 Clinical and pathological status of 167
patients in RT-PCR study
Figures:
1 Stages of the metastatic process 19
2 Prostaglandin metabolism in platelets 32
and endothelium
3 Pathways to blood coagulation 34
4 Major reactions of the intravascular 37
fibrinolytic pathway
5 Tumour cell arrest - adhesion to vascular 46
endothelium
6 Morphology of Mtln3 rat mammary carcinoma 72
cells in culture (x 625 magnification)
7 Rat lungs showing subpleural tumour 75
deposits prepared by the method of Wexler
8 Effect of Streptokinase on pulmonary tumour 81
seeding
12
9 Semi-quantitative measurement of plasma 
FDP
10 Effect of Streptokinase and rt-PA on 
pulmonary tumour seeding
11 Effect of Streptokinase and aspirin on 
pulmonary tumour seeding
12 Effect of Streptokinase and ticlopidine 
on pulmonary tumour seeding
13 Analysis of MAB-labelled tumour cells
a SM3/HMFG1 
b EMA
14 Analysis of MAB-labelled tumour cells
a Ber-EP4 
b MNF 116
15 One colour separation of leucocyte/tumour 
cell populations
a Scattergram of leucocyte/tumour cell 
populations 
b Percentage FL1 overlap
16 Two colour separation of leucocyte/tumour 
cell populations
a Scattergram of leucocyte/tumour cell 
populations 
b Percentage FL2 overlap 
c Percentage FLl overlap
17 Primer design
a 5' region of CK 18 gene 
b 5 1 region of DF3 gene
18 CK18/DF3 expression in primary breast 
carcinomas and peripheral blood
a electrophoretic analysis 
b autoradiographic analysis
19 Sensitivity assay for the DF3 gene
2 0 RT-PCR analysis of peripheral venous 
blood from patients undergoing surgery 
for benign and malignant disease
a pre-operative 
b operative 
c post-operative
88
100
111
114
133
134 
136
139
153
160
162
164
169
170
171
13
LIST OF ABREVIATIONS
ADP Adenosine Diphosphate
CAM Cell Adhesion Molecule
cDNA Complementary Deoxyribonucleic Acid
CK 18 Cytokeratin 18
EMA Epithelial Membrane Antigen
FCS Foetal Calf Serum
FDP Fibrin(ogen) Degradation Products
FITC Fluorescein Isothiocyanate
FSC Forward Scatter
F 344 Fischer 344
F10/DMEM 1:1 mixture of Hams' F10 and Dulbecco's
Modified Eagles' Medium
HMFG Human Milk Fat Globule Membrane
HMW- High Molecular Weight-kininogen
kininogen
LFA-I Leucocyte Function Antigen
(Integrin alpha-chain)
MAB Monoclonal Antibody
mRNA Messenger Ribonucleic Acid
MTT 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide 
PBS Phosphate Buffered Saline
PCR Polymerase Chain Reaction
PE Phycoerythrin
PEM Polymorphic Epithelial Mucin
rt Reverse Transcriptase
rt-PA Recombinant Tissue Plasminogen Activator
SSC Side Scatter
TBE Tris-Borate Buffer
TCIPA Tumour Cell-Induced Platelet Aggregat
u-PA Urokinase-type Plasminogen Activator
15
ACKNOWLEDGEMENTS
I would like to express my thanks to the following 
people who made this thesis possible:
The Bons Secours Hospital for their financial support
Dr J Plumb of Medical Oncology, Garscube for her 
assistance with tissue culture
Dr J Love at the Department of Statistics, University 
of Glasgow for her help with analysis of data
Mr D McMurdo and his colleagues in the Animal House, 
Glasgow Royal Infirmary for their assistance
Mr R Barron and his colleagues at the Department of 
Haematology, University School of Vetinary Medicine, 
Garscube for their assistance with the FDP study
Boerhinger Ingelheim, FRG, who supplied rt-PA used in 
all experiments
Dr A Campbell and Mr J Clark in the Department of 
Biochemistry, University of Glasgow for their help and 
advice with the flow cytometry studies
Dr G Birnie and his staff, Beatson Institute for Cancer 
Research, Garscube for their helpful criticism and 
advice with the PCR study
In particular I would like to thank Mr A Purushotham 
for his advice, helpful criticism, patience and support 
during the last two years
Finally I would like to thank Professor WD George for 
giving me the opportunity to perform these studies
16
DECLARATION
I declare that this thesis has been composed by myself, 
and that the work described herein was performed by me, 
or by myself in conjunction with others. The laboratory 
tests for analysis of Fibrin(ogen) Degradation 
Products, described in Chapter 2, were performed by Mr 
Barron, Department of Haematology, University School of 
Vetinary Medicine, Garscube. Statistical analysis of 
all the work described was supervised by Dr J Love, 
Department of Statistics, University of Glasgow. All 
other work described herein was performed entirely by 
myself. This work has not been presented at any 
previous application for a degree by myself or others.
The work described in this thesis has been presented at 
the following meetings of scientific societies:
December 1992 British Association of
Surgical Oncology, London
December 1992 Scottish Society for Experimental 
Medicine, Glasgow
January 1993 Surgical Research Society,
London
March 19 93 7th Meeting of the Academic 
Departments of Surgery in 
Europe (ADSE),
Free University of Amsterdam, 
The Netherlands
January 1994 Surgical Research Society, 
London
February 1994 Society of University Surgeons, 
University of California, Los Angeles, 
Jackson, Mississippi,
United States of America
Publications:
Inhibition of pulmonary tumour seeding by antiplatelet 
and fibrinolytic therapy in an animal experimental 
model. Brown DC, Purushotham AD, George WD. J Surg 
Oncol 1994; 55: 154-159.
Streptokinase inhibits pulmonary tumour seeding in an 
animal experimental model. Purushotham AD, Brown DC, 
McCulloch P, Choy A, George WD. J Surg Oncol 1994; 57: 
3-7 .
Detection of intra-operative tumour cell dissemination 
in patients with breast cancer using reverse 
transcription and the Polymerase Chain Reaction. Brown 
DC, Purushotham AD, Birnie GD, George WD. Surgery 1994; 
In press
17
INTRODUCTION
1. THE MECHANISM OF DEVELOPMENT OF METASTATIC DISEASE
1.1 Pathogenesis of metastasis
The term "metastases" was coined by the French 
physician, Joseph Claude Recamier in his 1829 treatise 
Recherches du Cancer (Recamier, 1829). Previously, 
surgeons had recognized that malignant tumours could 
invade locally and spread to draining lymph nodes but 
distant metastases were thought to be distinct tumours. 
Recamier provided anatomic evidence that distant
metastases arose from cancer cells shed into the 
circulation by the primary tumour. Halsted (1907)
suggested that such haematogenous dissemination was 
secondary to lymphatic invasion but later pathological 
studies established that malignant tumours could invade 
the vascular system directly (Friedel et al, 1965), 
even in the absence of lymphatic involvement (Salsbury, 
1975) .
Metastasis is now defined as the ability of a 
tumour to disseminate via lymphatic or vascular
channels to a distant, non-contiguous site and it is 
the most important criterion distinguishing benign from 
malignant tumours. The resistance of metastases to 
conventional therapies explains why the cure rate for 
the major cancers has remained relatively unchanged
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despite a significant improvement in our understanding 
as to their aetiology, biology and treatment (Fidler et 
al, 1987). Considerable evidence has established that 
the metastatic process is a complex sequential pathway 
which few tumour cells complete successfully (Weiss et 
al, 1986). Primary tumours possess heterogeneous 
metastatic properties and only a minor subpopulation of 
cells have the necessary intrinsic properties to 
complete all stages of the metastatic process (Fidler 
et al, 1990) . This successful metastatic cell has been 
likened to a "decathlon champion" (Fidler et al, 1978) 
which can successfully interact with the host 
environment and survive many lethal events to 
eventually grow into a metastasis. The metastatic 
process can be divided into five stages: 1) invasion
of host tissues and penetration of the vascular system 
2) dissemination by the circulation and evasion of host 
defences 3) adhesion to vascular endothelium 4) 
extravasation into host tissues and 5) secondary tumour 
growth (Figure 1).
Tumour vascularisation (angiogenesis) is 
essential for growth and metastasis. Once a tumour 
reaches a critical diameter of 2-3mm, its nutritional 
requirements can no longer be met by simple diffusion 
and further growth requires the development of a 
vascular system (Folkman et al, 1972). Specific 
angiogenic molecules released by the tumour or adjacent 
macrophages induce both vascularisation and lymphatic 
proliferation (Polverini et al, 1984; Folkman et al,
Figure 1
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1989). The prevascular phase may persist for many years 
and is associated with a paucity of metastases while 
the vascular phase is associated with rapid tumour 
growth and dissemination (Brem et al, 1978; Sillman et 
al, 1981). The intensity of neovascularization has been 
shown to correlate with the development of both local 
lymph node and distant metastases suggesting that these 
immature blood vessels, which lack an organised 
extracellular matrix may facilitate the entry of tumour 
cells into the circulation (Blood et al, 1990; Weidner 
et al, 1991) . This process may be enhanced by tissue 
pressure generated by growth-associated expansion in 
the parent tumour (Hori et al, 1983). Invasion through 
intact basement membrane of existing mature blood 
vessels by enzymatic degradation of the extracellular 
matrix may also occur. Tumour production of proteolytic 
enzymes capable of such activity has been shown to 
correlate with metastatic potential (Nakajima et al, 
1983; Wooley, 1984) but the relevance of this process 
to intravasation as opposed to extravasation in 
secondary sites is unclear.
The presence of tumour cells in the bloodstream 
does not always determine that metastasis will occur. 
Although the majority of cells released from a primary 
tumour are potentially tumourigenic (Glaves and 
Mayhew, 1984), less than 1% of tumour cells are viable 
after 24 hours in the circulation and less than 0.1% 
survive to produce metastases (Fidler, 1970). 
Mechanical trauma and nutritional defficiency are
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thought to explain the short half-life of the majority 
of circulating cells (Sato and Suzuki, 1976; Weiss et 
al, 1985) . Antitumour immune activity may also 
contribute to cell loss and involves the participation 
of both specific and non-specific immune defence 
mechanisms including cytotoxic T lymphocytes, natural 
killer (NK) cells and mononuclear phagocytes (Wood et 
al, 1975; Fidler et al, 1980; Hanna et al, 1985). 
Individual tumour cell survival can be enhanced by 
aggregation with each other, with host cells, including 
platelets and lymphocytes (Fidler, 1977; Gasic, 1984; 
Updyke, 1986) or by adhesion to endothelium (Korach et 
al, 1986) . It is thought that tumour cells placed 
within the central zone of such emboli are better 
protected from mechanical and immune destruction. 
Therefore, blood appears to be an extremely hostile 
environment for tumour cells which being derived from 
solid tissues, have no particular properties that 
enhance their survival in this environment. It would 
seem that tumour cells which minimize their
circulation time by encouraging early extravasation may 
have the greatest metastatic potential.
The arrest of tumour cells has been postulated 
to be a random process during which mechanical 
entrapment occurs in the microcirculation of the first 
organ encountered. This haemodynamic theory was first 
postulated by Ewing (1928) and has since been confirmed 
by numerous animal models which have demonstrated that 
the lungs are the preferential site of metastasis after
22
intravenous tumour cell injection (Proctor et al, 197 6; 
Becker et al, 1978) and the liver after intraportal 
injection (Fisher and Fisher, 1965; Vaage, 1973). 
However, animal studies using radiolabelled tumour 
cells injected into the arterial system have revealed 
that certain tumours preferentially metastasise to 
specific organs independent of vascular anatomy, rate 
of blood flow and number of tumour cells delivered 
(Murphy et al, 1988) .
Clinical observations describing a non-random 
pattern of visceral metastasis were first reported for 
breast cancer by Paget (1889). He concluded that 
certain tumour cells (the seed) had specific affinity 
for certain organ environments (the soil). Experimental 
verification of this "seed-soil" hypothesis has
recently been provided by in vitro studies
demonstrating preferential adhesion of tumour cells to 
the preferred site of metastasis - melanoma cells to 
lung endothelium (Johnson et al, 19 91) , mammary
carcinoma cells to lymphatic endothelium, glioma cells 
to brain-derived capillary endothelium (Auerbach et al, 
1987) and liver-metastatic tumour cells to hepatic 
sinusoidal endothelium (Roos et al, 1984) . Cell 
adhesion molecules, which encompass four major 
families, integrins, cadherins, immunoglobulins and 
selectins, are now thought to mediate the adhesion of 
tumour cells to target organ capillary endothelium 
(Honn and Tang, 19 92) . A correlation has been shown 
between the expression of specific cell adhesion
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molecules and the metastatic potential of various human 
tumours. Expression of the intercellular adhesion 
molecule-1 (ICAM 1), the ligand for the integrin 
receptor lymphocyte function-associated-1 (LFA-1) found 
on leucocytes, has been implicated in melanoma 
metastasis (Johnson et al, 1989), ICAM 2, PECAM 1 and 
CD 44 in lymphoma metastasis (Roos et al, 1991) and 
ELAM-1 in colon metastasis (Rice et al, 1988) . These 
experimental studies suggest that the site selectivity 
of bloodborne metastasis is predominantly determined by 
the pattern of surface adhesion receptors expressed by 
tumour cells and endothelium.
Extravasation requires penetration of a mature 
basement membrane and thus is dependent upon the 
production of hydrolytic enzymes capable of degrading 
specific matrix molecules (Nakajima et al, 1983; 
Wooley, 1984). In addition, tumour cell invasion may be 
enhanced by degraded fragments of the extracellular 
matrix which are chemotactic, thereby stimulating 
tumour cell motility (Blood et al, 1988; Albini et al, 
1987). Increased motility is frequently observed in 
highly metastatic tumour cells (Geiger and Raz, 1984; 
Young et al, 1985) . The final stage of secondary tumour 
growth is dependent on the ability of individual tumour 
cells to respond selectively to growth modulators in 
the surrounding microenvironment and to promote 
angiogenesis.
24
1.2 Metastatic heterogeneity of malignant neoplasms
The inefficiency of the metastatic process led 
researchers to question whether the development of 
metastases represented the fortuitous survival and 
growth of a few tumour cells or whether it simply 
represented the selective survival of a unique 
subpopulation of tumour cells possessing special 
properties. Ewing suggested that the pattern of 
metastasis was merely a consequence of anatomical and 
haemodynamic factors (Ewing, 1929). While circulatory 
anatomy may influence the distribution of metastasis 
the "seed-soil" hypothesis of Paget demonstrated that 
the pattern of metastasis was non-random and not due to 
chance.
The first experimental evidence for pre-existing 
metastatic heterogeneity of malignant tumours was 
provided by Fidler and Kripke (1977) with the murine 
B16 melanoma. Using a modification of the fluctuation 
assay of Luria and Delbruck (1943), they demonstrated 
considerable variation in the ability of different 
tumour cell clones, each derived from an individual 
cell isolated from the parent tumour, to produce 
pulmonary metastasis after intravenous administration. 
Similar findings were subsequently shown for human 
tumour lines and fresh tumour using nude mice as models 
for metastasis (Fidler, 1986). The idea that neoplasms 
contained subpopulations of tumour cells with different 
metastatic propensities was thus established. The
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source of such heterogeneity was however difficult to 
perceive as the majority of naturally occuring and 
induced neoplasms were known to be unicellular in 
origin (Nowell, 1976; Vogelstein, 1985). Clinical and 
histopathological observations that benign tumours 
could change over a period of time into malignant
tumours led to the concept of neoplastic progression. 
This was defined as "acquisition of permanent,
irreverible qualitative changes in one or more 
characteristics of a neoplasm" (Foulds, 1975) . Studies 
using virally-transformed murine fibroblasts showed 
that acquired phenotypic heterogeneity could produce 
subpopulations of tumour cells with different
metastatic potentials at an early stage of development
(Fidler, 1981). Furthermore, karyotypic analysis of 
primary tumours and their metastases showed that tumour 
progression was associated with increasingly altered 
karyotype and ploidy of metastatic subpopulations 
(Nowell, 1989). Comparison of metastatic and non­
metastatic cloned lines isolated from different rodent 
neoplasms established that highly metastatic cells were 
consistently phenotypically and genotypically less 
stable than their non-metastatic counterparts (Cifone 
and Fidler, 1982; Kaden et al, 1989) . Thus it appears 
that genetic instability enables highly metastatic 
cell subpopulations to undergo rapid phenotypic 
diversification. Current therapeutic modalities that 
destroy most, but not all, tumour cell subpopulations 
may enable these highly metastatic subpopulations to
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survive and produce new variants with even greater 
metastatic properties (Poste, 1986).
2 THE HAEMOSTATIC SYSTEM
The mechanism of haemostasis involves a complex 
interaction between the vascular endothelium, platelets 
and the coagulation and fibrinolytic pathways. After 
vascular injury, transient primary haemostasis is 
achieved by arterial vasoconstriction and the formation 
of a platelet plug. More permanent haemostasis is 
achieved by activation of coagulation and formation of 
a fibrin clot. This secondary phase forms a platform 
for endothelial cell growth and the release of fibrin 
degradation products. In addition, plasminogen 
activation stimulates angiogenesis and repair of the 
vascular wall while fibrinolysis and collagenase 
activity remove debris. A complex system of checks 
ensures that activation of the haemostatic system is 
balanced and does not progress to either life 
threatening haemorrhage or disseminated intravascular 
coagulation. The role of each system is discussed 
below.
2.1 Vascular Endothelium
Vascular endothelium contributes to a normal 
haemostatic balance in two ways. Firstly, a healthy 
intact endothelium provides an interface separating
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platelets and coagulation factors from thrombogenic 
components of the vascular subendothelium. Platelets 
are shielded from activation factors of the 
subendothelial matrix including von Willebrand factor 
(vWF), collagen and fibronectin while extrinsic and 
intrinsic activation of the coagulation pathway is 
prevented by endothelial shielding of tissue 
thromboplastin and surface contact activators 
(Koteliansky et al, 1981; Osterud, 1984; Stel et al, 
1985). In addition, vascular endothelial cells 
contribute to haemostatic balance by synthesizing and 
secreting both anticoagulants and procoagulants.
The major anticoagulants synthesized by 
endothelium are prostacyclin (PGI2) and tissue 
plasminogen activator (t-PA) . PGI2 is the major 
arachidonic acid metabolite of endothelium and is a 
potent vasodilator and inhibitor of platelet 
aggregation (Honn et al, 1983). Tissue plasminogen 
activator is a powerful fibrinolytic agent and has a 
high affinity and specificity for fibrin-bound 
plasminogen where it causes enzymatic degradation of 
the latter into plasmin and consequently fibrinolysis 
(Collen et al, 1989).
The major procoagulant factors produced by 
endothelial cells are vWF and fibronectin. These large 
glycoprotein molecules are stored in endothelial cells 
and the alpha granules of platelets. During platelet 
activation they are released and together with 
circulating vWF and fibronectin preferentially bind to
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a specific glycoprotein receptor Ilb-IIIa, on the 
membranes of activated platelets (Plow et al, 1985; 
Haverstick et al, 1985). At the same time, these 
adhesive proteins bind to receptors on the 
extracellular matrix and thus serve as cables and 
connectors that link activated platelets to each other 
and to the subendothelial extracellular matrix (Hynes 
et al, 1987) thereby enhancing platelet aggregation and 
adhesion.
Several structurally unrelated anticoagulants 
are also produced by endothelium or activated on 
endothelial surfaces. This family of naturally occuring 
anticoagulants act on endothelial surfaces to inhibit 
terminal stages of the coagulation pathway. The 
principal components of the endothelial antithrombin 
system are antithrombin III which inactivates thrombin 
on the surface of endothelium (Busch et al, 1982), and 
two vitamin-K dependent enzymes: protein C and protein 
S which inactivate coagulation factors Va and Villa 
(Stern et al, 1986) .
In summary, it is clear that the endothelium has 
an important role in maintaining haemostatic balance. 
Loss of endothelial lining as a result of acute 
vascular injury, chronic endothelial damage by 
atherosclerosis or hypertension deprives the vessel of 
the intrinsic anticoagulant protective mechanisms 
outlined above. Furthermore, exposure of the 
thrombogenic constituents of the subendothelial matrix, 
including vWF, fibronectin and tissue thromboplastin,
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leads to platelet adhesion, the initial event in 
platelet plug formation.
2.2 Platelets
Platelet structure
Platelets are discoid fragments of marrow 
megakaryocytes that normally circulate for about 10 
days in numbers ranging from 200 000 to 400 000
platelets/ul. The surface membrane is composed of a 
typical trilaminar phospholipid structure interspersed 
with proteins and glycoproteins anchored by hydrophobic 
roots. The three major groups of membrane 
glycoproteins, termed glycoproteins I, II and III 
possess receptor, transport and enzymatic functions. 
Cytoplasmic granules (alpha, dense and lysosomal) 
secrete agents essential for platelet adhesion and 
aggregation including vasoactive amines, adenosine 
diphosphate (ADP), beta-thromboglobulin and
prostaglandins (Tuffin, 1991). Cytoplasmic microtubules 
composed of the contractile proteins actin and myosin 
are responsible for clot retraction in addition to 
shape change and spreading during activation (Gerrard 
et al, 1976) .
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Platelet function
The mechanism by which platelets participate in the 
formation of a haemostatic plug involves initial 
adhesion to exposed subendothelial matrix at the site 
of vascular injury. This is followed by aggregation of 
platelets and the formation of a platelet plug. 
Finally, platelets initiate procoagulant activity and 
facilitate the generation of thrombin and formation of 
a fibrin clot.
Platelet adhesion and aggregation require the 
interaction of platelet surface glycoproteins with 
adhesive proteins (ligands) present in plasma and 
platelet granules. Two of the major surface 
glycoproteins, termed lib and Ilia, exist as a non- 
covalent 1:1 complex and serve as a common receptor for 
fibrinogen (Bennett et al, 1983), fibronectin (Gardner 
and Hynes, 1985), vitronectin (Pytela et al, 1986) and 
vWF (Ruggeri et al, 1982) . The interaction of integrin 
receptors and ligands is an essential component in 
cell-matrix and cell-cell adhesion in many 
physiological mechanisms including haemostasis (Hynes,
1987). vWF and thrombospondin are the major adhesive 
proteins which facilitate platelet-subendothelial 
adhesion whereas primary aggregation is predominantly 
associated with the binding of fibrinogen (Mayer and 
Baumgartner, 1983; Peerschke, 1986). Exposed 
subendothelial collagen normally initiates platelet 
activation but other agonists released by damaged
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tissue or previously activated platelets including ADP, 
thrombin and adrenaline, can stimulate further platelet 
adhesion or primary aggregation. The second wave of 
aggregation termed the "release reaction" is 
characterised by the release of ADP and arachidonic 
acid and results in additional fibrinogen binding and 
stabilization of platelet aggregates (Colman, 1986). 
Platelet activation is also associated with 
transformation to a discoid shape and surface spreading 
thereby increasing the surface area for adhesion.
Mechanical and agonist stimulation also liberate 
arachidonic acid from membrane phospholipid leading to 
prostaglandin synthesis by activation of cyclo- 
oxygenase and lipoxygenase pathways (Neufield and 
Majerus, 1983). The major products of the cyclo- 
oxygenase pathway are prostacyclin (PGI2) and 
thromboxane A2 (TXA2) while activation of the 
lipoxygenase pathway produces the hydroperoxides, 
hydroperoxyeicosatetraenoic acid (HPETE) and
hydroxyeicosatetraenoic acid (HETE) (Figure 2). TXA2 is 
the predominant product of arachidonic acid metabolism 
in platelets and is a powerful stimulator of platelet 
aggregation and arterial vasoconstriction. As
described earlier, endothelial cells defend their non- 
thrombogenic surfaces by secreting PGI2 and normally an 
equilibrium exists between endothelial PGI2 and 
platelet-derived TXA2. The increased release of TXA2 
during platelet activation leads to an imbalance which 
favours platelet aggregation.
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Adequate haemostasis cannot be achieved by
platelet deposition alone. Reinforcement of this
relatively weak platelet-subendothelial bond is
provided by fibrin and is essential to prevent 
detachment of the platelet plug by intravascular blood 
flow. Platelets participate in the formation of fibrin 
by providing a favourable surface for the binding of 
co-factors and enzymes essential to the generation of 
thrombin.
2.3 Coagulation pathway
The coagulation pathway culminates in the conversion of 
the soluble plasma protein fibrinogen, to insoluble 
fibrin transforming plasma from a solution to a gel. 
The rate of this conversion is greatly increased by the 
assembly of co-factors and enzymes in complexes on 
platelets. This requires a complex series of reactions 
which convert sequentially inert plasma precursors into 
their active forms. With the exception of factors V, 
VII and high molecular weight kininogen, which are
peptide co-factors, activated coagulation factors are 
proteolytic enzymes. Activated factors then activate 
factors down the line domino fashion by a process of 
limited proteolysis.
Coagulation is mediated by two distinct pathways 
which share the final three steps of: activation of
factor X, prothrombin to thrombin conversion and fibrin 
formation (Figure 3).
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The extrinsic pathway is initiated by the 
release of tissue factor (thromboplastin) by vascular 
endothelial cells, macrophages and neutrophils at the 
site of vessel disruption. Thromboplastin then 
interacts with factor VII to form a complex with 
platelet phospholipid which, in the presence of calcium 
ions, activates factor VII (Vila). The subsequent 
activation of factor X by factor Vila also occurs in 
the presence of platelet phospholipid and calcium ions.
The intrinsic pathway is initiated by exposure 
of plasma to non-endothelial surfaces including 
basement membrane, collagen and platelet procoagulants. 
Platelets facilitate factor XII activation by binding 
factor XII to a receptor that alters its conformation 
and enhances proteolysis. Factor XII may also be 
activated by a contact activation complex, composed of 
high molecular weight kininogen (HMWK) complexed to 
prekallikrein or factor XI and anchored to an 
endothelial surface. The interaction of factor XII with 
this complex creates a positive feedback loop which 
leads to the generation of factor XIa, IXa and 
subsequently factor Xa.
The ability of factor Xa to activate prothrombin 
is accelerated several thousand-fold by 1:1 binding of 
factor Va and calcium ions to platelet phospholipid 
forming a prothrombinase complex. Thrombin then 
catalyses the final stage of plasma fibrinogen 
conversion to fibrin by limited proteolysis and removal 
of fibrinopeptides A and B. These fibrin monomers then
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polymerize to form double-stranded protofibrils which 
become covalently crosslinked by factor XIII to form 
interwoven fibrin polymers (Weisel et al, 1983).
Vitamin K is required for the synthesis 
(carboxylation) of prothrombin together with factors 
VII, IX and X by hepatocytes. These carboxyl groups are 
essential for the binding of calcium ions and the 
formation of stable complexes with platelet 
phospholipid (Esmon et al, 1975).
2.4 Fibrinolytic pathway
Fibrin clot serves a temporary haemostatic function and 
simply provide a stop-gap measure until healing can 
restore an intact endothelium. Fibrinolysis is an 
integral part of the repair process and ensures 
complete restoration of blood flow after vessel repair. 
The fibrinolytic pathway is initiated by enzymes termed 
plasminogen activators that either are "intrinsic" 
components of plasma or are released or secreted by 
"extrinsic" tissue including vascular endothelium or 
macrophages. These activators then convert the plasma 
protein plasminogen into the fibrin-splitting protease 
plasmin (Figure 4).
Surface contact activation of the coagulation 
pathway is accompanied by the generation of plasmin via 
the identical enzymatic sequence of proteolysis of 
factor XII, HMW Kininogen, kallikrein and factor XI 
(Mandle and Kaplan, 1979).
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Extrinsic tissue plaminogen activator (t-PA) is 
released from endothelial lysosomes of damaged vessels 
and together with plasminogen binds to specific
receptors on exposed fibrin strands (Tran-Thang et al, 
1984) . This preferential concentration of t-
PA/plasminogen complexes on fibrin facilitates rapid 
conversion of plasminogen to plasmin and in addition 
protects plasmin from degradation by alpha 2- 
antiplasmin. Although some t-PA enters the plasma, 
systemic activation of fibrinolysis is minimal as a 
result of the short lifespan of proteolytic activator
and the immediate neutralizing effect of alpha 2-
antiplasmin.
Fibrin degradation products (FDP) released from 
the clot by plasmin can impair coagulation by binding 
to thrombin at its fibrinogen-receptor site or binding 
to the fibrin clot and weakening its structure. If the 
macrophage clearing system for FDP is overwhelmed, 
systemic release can lead to platelet and endothelial 
dysfunction and increased capillary permeability, in 
addition to systemic activation of fibrinolysis.
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3 CANCER AND HAEMOSTASIS
3.1) Clinical evidence for altered coagulation in 
malignant disease.
A high incidence of superficial venous thrombosis in 
patients with gastric cancer was first noted by Armand 
Trousseau in 1865 and provided the earliest evidence to 
suggest an association between the haemostatic system 
and malignant disease. Over the following century many 
studies reported numerous thrombotic and haemorrhagic 
complications in patients with cancer. Pancreatic 
carcinoma has been associated historically with a high 
incidence of thomboembolic disease (TED) (Sproule, 
1938; Sack et al, 1977) but a wide variety of malignant 
tumours may disrupt the haemostatic balance causing 
venous and arterial thrombosis, migratory 
thromboembolism, pulmonary embolism and non-bacterial 
thrombotic endocarditis (Goodnight, 1974; Weick, 1978; 
Sack et al, 1977; Rickies and Edwards, 1983). In 
particular, mucin-secreting tumours of the ovary, 
prostate and gastrointestinal tract can cause 
significant disturbance of haemostasis (Miller et al, 
1967; Goodnight, 1974). This has been attributed to the 
secretion of plasminogen activator (Soong and Miller, 
1970) or to the presence of factor X activator in mucus 
(Pineo et al, 1974) . The overall incidence of TED is 
within the range 1-11% (Nand and Messmore, 1990) but
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may increase with therapeutic intervention and 
chemotherapy (Kasimis and Spiers, 1979; Seifter et al, 
1985; Levine et al, 1988). At postmortem, 74% of 
patients with cancer have evidence of underlying non- 
bacterial thrombotic endocarditis (NBTE) (Sack, 1977) . 
NBTE is seen most commonly with mucin-producing 
adenocarcinomas and may lead to limb gangrene and 
cerebro-vascular occlusion (Rosen and Armstrong,1973).
The susceptibility of the haemostatic system to 
alteration by malignant disease is such that a 
hypercoagulable state may indicate occult malignancy 
(Goldhaber et al 1987, Adamson and Currie, 1993). 
Pulmonary embolism or deep venous thrombosis may 
precede the development of malignant neoplasms of the 
lung, breast, uterus and gastrointestinal tract by up 
to five years (Gore et al, 1982; Goldberg et al, 1987). 
Activation of coagulation and fibrinolysis in patients 
with malignant disease may relate to tumour stage and 
prognosis (Seitz et al, 1993). The importance of 
subclinical activation of coagulation as a possible 
marker for malignancy has led to intensive laboratory 
investigation of patients with cancer.
3.2) Laboratory evidence for altered coagulation in 
patients with cancer.
Subclinical dysfunction of haemostasis can be 
identified in up to 92% of patients with cancer (Sun et 
al, 1979). Quantitative alteration in platelets,
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usually thrombocytosis, occurs in up to 60% of patients 
whereas functional abnormalities are uncommon and may 
be related to the presence of fibrin degradation 
products (Rickies and Edwards, 1983).
The most common clotting abnormalities seen are 
increased levels of fibrin(ogen) degradation products 
(FDP) and elevated fibrinogen levels (Davis et al, 
1969; Sun et al, 197 9; Rickies and Edwards, 1983; Van 
Duijnhoven et al, 1993). Some patients show prolonged 
prothrombin and activated partial thromboplastin times. 
Elevated Fibrinopeptide-A (FPA) levels are present in 
the majority (60-95%) of patients with local or 
disseminated malignancy (Peuscher et al, 1980; Mombelli 
et al, 1982). FPA is a short chain peptide cleaved from 
the alpha chain of fibrinogen by thrombin. Since the 
plasma half life is less than four minutes, plasma 
levels reflect ongoing coagulation and therefore the 
presence of intravascular thrombin. FPA levels appear 
to reflect the clinical response of patients with 
cancer and persistent elevation correlates with 
progressive disease and poor prognosis (Rickies et al, 
1983) .
Disseminated intravascular coagulation (DIC) is 
a disorder characterised by the initial deposition of 
fibrin thrombi in the microcirculation of many organs. 
Subsequent activation of the fibrinolytic system 
produces FDP which further stimulate plasmin production 
by positive feedback. In addition, FDP disrupt platelet 
function and increase capillary permeability. The
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continuous consumption of coagulation factors and 
platelets eventually progresses to a decompensated, 
haemorrhagic state. Although subclinical DIC is common 
in malignancy, only 9-15% of patients develop DIC of 
clinical significance (Belt et al, 1978; Sun et al, 
1979) and this is usually associated with mucin- 
secreting adenocarcinomas (Belt et al, 1978), gram 
negative sepsis or liver impairment (Al-Mondhiry, 
1975) .
3.3 Role of fibrin and the fibrinolytic system in the 
metastatic process
The earliest evidence to suggest a role for the
coagulation pathway in the spread of malignant disease 
came from post mortem studies of Theodore Bilroth in 
1878 (Bilroth, 1878) . He described the association of 
human tumour cells with thrombi and suggested that the 
spread of tumours could be brought about by the 
circulation of thrombi-containing tumour cells. The
studies of O'Meara (1958) demonstrated that primary 
carcinomas were surrounded by a fibrin mesh and that 
extracts of these tumours could activate the 
coagulation pathway (O'Meara and Thornes, 1961). 
Subsequent studies demonstrated that fibrin deposition 
occured within hours of tumour implantation and
remained throughout the period of tumour growth 
(Dvorak, 1984). Fibrin is thought to possibly enhance 
tumour integrity by providing a scaffold for tumour
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cell growth, enhancing angiogenesis (Dvorak, 1986) or 
protecting against immune destruction (Gunji and 
Gorelik, 1988; Cardinali et al, 1990).
Extravascular fibrin is not a consistent finding 
and immunohistochemical analysis has demonstrated that 
many tumours lack a surrounding cocoon of fibrin 
(Costantini et al, 1991a,b; Wojtukiewicz et al, 1989a). 
These tumours also vascularise and proliferate 
indicating that while fibrin may contribute to tumour 
progression, it is not essential. Furthermore, many 
tumours including breast, colon and prostate, express 
urokinase-type plasminogen activator (u-PA) rather than 
promotors of coagulation (Constantini et al, 1991a,b; 
Wojtukiewicz et al, 1989b, 1991). Several studies have
correlated plasminogen activator (PA) production with 
invasive and metastatic potential (Ossowski, 1983; 
Skriver et al, 1984; Mignatti et al, 1986; Reich et al, 
1988; Cajot et al, 1989). Since plasmin is capable of 
digesting many biological barriers either directly or 
by activation of proenzymes of metalloproteinases 
(Tryggvason et al, 1987; Murphy et al, 1989), it 
appears that tumour plasminogen activator (PA) may 
facilitate tumour growth and invasion by initiating the 
proteolytic cascade pathway, leading to degradation of 
extracellular matrix (Reiter et al, 1993).
Ossowski (1991) has demonstrated in a murine 
model that specific anti-PA antibodies do not prevent 
metastasis once tumour cells have gained access to the 
circulation (Ossowski, 1991). In addition, PA
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production has recently been shown to correlate with 
the metastatic potential of melanoma cells after 
subcutaneous implantation but not after intravenous 
injection (Quax, 1991). While these findings indicate 
an early role for PA in the metastatic cascade by 
enhancement of intravasation, several studies have 
reported an association between tumour PA production 
and the metastatic potential of intravenously 
inoculated tumour cells (Hearing et al, 1988, Axelrod 
et al, 1989). On balance, the current evidence suggests 
that tumour PA promotes metastasis by facilitating the 
penetration of the vascular basement membrane thereby 
enabling tumour cells to enter the bloodstream (Dano et 
al, 1985; Liotta, 1986) . The role of PA in the later 
stage of extravasation remains to be clarified.
Evidence supporting fibrin involvement in 
metastasis has come from microscopy studies which have 
looked at the fate of intravenously injected tumour 
cells in numerous animal models of artificial 
metastasis. Circulating tumour cells arrest in the 
microcirculation of target organs surrounded by a 
meshwork of fibrin and platelets (Wood, 1958; Jones et 
al, 1971; Warren and Vales, 1971; Chew and Wallace, 
197 6) . It is currently believed that fibrin enhances 
the metastatic process by facilitating the adhesion of 
tumour cells to vascular endothelium by acting as an 
intercellular glue (Francis, 1989).
In summary, these studies suggest that fibrin 
may have opposing effects on the metastatic process. By
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forming a protective barrier around the primary tumour, 
fibrin may prevent penetration of the vascular basement 
membrane thereby reducing the possibility of 
haematogenous dissemination. In contrast, fibrin may 
also promote metastasis by facilitating the entrapment 
of tumour cells in the microcirculation within a 
fibrin-platelet mesh (Figure 5) . The relative
importance of these opposing effects on the metastatic 
pathway is unknown.
3.4 Tumour Procoagulant Activity
An association between in vitro thrombogenesis and in 
vivo fibrin formation was first described by Lawrence 
(1952). Rabbit V2 carcinoma cells demonstrated similar 
clot-promoting properties to rabbit brain 
thromboplastin in vitro and were equally effective in 
the production of thrombosis in vivo after intravenous 
inoculation. The inhibition of this in vivo effect with 
heparin and dicoumarol suggests that tumour cell- 
induced procoagulant activity (PCA) acts via the 
coagulation pathway. The isolation of tumour PCA in 
centrifuged cell-free supernatants or cell-free ascitic 
fluid from various tumour cell lines (Dvorak et al, 
1983; Seitz et al, 1993) has now established three 
subgroups of PCA:
1) Tissue factor (TF) like procoagulants initiate the 
extrinsic pathway of coagulation by increasing the 
activity of Factor Vila which in turn catalyzes the
Figure 5
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conversion of Factor X to Xa (Dvorak et al, 1983) . TF 
was originally identified in buffy coat cells in acute 
promyelocytic leukaemia (Gralnick and Abrell, 1973) but 
has since been identified in a variety of malignant 
tumours including human . leukaemias, lymphomas, 
adenocarcinomas, osteogenic sarcomas and various murine 
malignancies.
2) Many malignant tumours produce a procoagulant, which 
unlike tissue factor, does not require factor VII for 
its activity (Gordon et al, 1975; Curatolo et al, 1979; 
Hilgard and Whur, 1980). This procoagulant activates 
factor X directly and a strong positive correlation has 
been demonstrated between metastatic potential and 
tumour procoagulant (Gilbert and Gordon, 1983). These 
single chain cysteine proteases are produced by many 
human malignancies including breast, lung and colon. 
While the procoagulant activity of benign melanocytic 
lesions is dependent on factor VII for activity and can 
be blocked by concavalin A a tissue factor inhibitor, 
malignant melanomas exhibit procoagulant activity which 
is independent of factor VII and unaffected by 
concavalin A (Gordon et al, 1979; Donati et al, 1986). 
This suggests that benign tissue produces tissue factor 
and malignant transformation is associated with tumour 
procoagulant production.
3) Other tumour-associated procoagulants have been 
isolated from human and animal tumours, but
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contamination with TF-producing macrophages and 
monocytes have prevented confirmation (Lawrence et al, 
1952; Boggust et al, 1963; Svanberg, 1975).
3.5 Role of platelets
The first evidence to suggest an association between 
platelets and metastasis came from the work of Schmidt 
(1903) who described platelet aggregates surrounding 
human tumour cells in pulmonary arterioles. Later, 
electron microscopic studies in animal models 
demonstrated that after intravenous injection tumour 
cell emboli arrest in pulmonary capillaries and 
arterioles surrounded by a meshwork of fibrin and 
platelets (Jones et al, 1971; Warren and Vales, 1972; 
Sindelar et al, 1975) . Gasic and co-workers (1968) 
were the first to provide experimental evidence for 
the role of platelets in the metastatic process by 
showing a reduction in the metastatic potential of 
intravenously injected tumour cells in mice rendered 
thrombocytopenic by neuraminidase (Gasic et al, 1968). 
A similar antimetastatic effect was shown after 
thrombocytopenia induced by platelet antiserum which 
was completely reversed by platelet transfusion (Gasic 
et al, 1968) .
Evidence confirming the importance of tumour 
cell-induced platelet aggregation (TCIPA) in the 
metastatic process has come from three separate lines
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of investigation. Firstly, experiments have 
demonstrated a positive correlation between the ability 
of tumour cells to aggregate platelets in vitro and 
their metastatic potential in vivo (Gasic et al, 1973; 
Pearlstein et al, 1980; Tohgo et al, 1986; Mahalingham 
et al, 1988) . Secondly, PGI2 and its analogues such as 
iloprost and cicaprost possess strong anti-TCIPA 
properties and have a potent antimetastatic effect in 
vivo (Honn et al, 1981; Giraldi et al, 1990; Schneider 
et al, 1990). Finally, recent experiments have shown 
that synthetic peptides or monoclonal antibodies 
directed against the common platelet adhesive protein 
receptor for fibronectin, vWF and fibrinogen, inhibit 
tumour-platelet adhesion in vitro and metastasis in 
vivo (Karpatkin et al, 1988; Nierodzik et al, 1991; 
Sheu et al, 1993). Collectively, these experiments 
indicate that the ability of tumour cells to activate 
and aggregate platelets constitute an important aspect 
of the metastatic process.
The mechanism by which tumour cells trigger the 
activation of platelets remains to be clarified but 
current evidence suggests that initial activation 
involves either the generation of thrombin or ADP by 
tumour cells (Bastida, 1982, 1988; Honn et al, 1992).
Platelet activation subsequently leads to the release 
of a host of bioactive substances including adhesive 
glycoproteins (integrins, immunoglobulins and 
selectins) and arachidonic acid metabolites (TXA2 and 
12(S)-HETE). Furthermore, platelet activation leads to
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the rapid surface targeting and functional activation 
of surface adhesion receptors (Honn et al, 1992). These 
adhesion molecules together with the release products 
are thought to strengthen platelet-tumour cell bonding 
and irreversible TCIPA, thereby potentiating tumour 
metastasis. In support of this theory it has been shown 
that many tumour cells express the platelet adhesion 
molecule allb£3 and that antibodies against aIIbB3
inhibit tumour cell adhesion to platelets in vitro and 
metastasis in vivo (Karpatkin et al, 1988) . Platelet
membrane P-selectin may also be involved in tumour
cell-platelet interactions as various tumour cells 
express ligands for P-selectin while antibodies to P- 
selectin inhibit adhesion of tumour cells to activated 
platelets (Stone et al, 1993).
Arachidonic acid metabolites are also important 
mediators of platelet activation. Their role in TCIPA 
has come from studies which have demonstrated that 
platelet aggregation induced by some tumour cells
correlates positively with production of the cyclo- 
oxygenase product TXA2 and the degree of malignancy 
(Pacchiarini et al, 1991). In addition, recent evidence 
has suggested that lipoxygenase metabolites of 
arachidonic acid may also have an important role in 
tumour cell-platelet interactions. Platelets and some 
tumour cells secrete the lipoxygenase metabolite 12 
(S)-HETE which is capable of stimulating both adhesion 
of tumour cells to endothelium (Liu et al, 1991) and 
cause reversible endothelial cell retraction (Tang et
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al, 1992). It has been suggested that tumour cell- 
platelet thrombi may produce a microenvironment of high 
12 (S)-HETE thereby enhancing tumour cell adhesion to 
vascular endothelium (Grossi et al, 1989) and 
accelerating the process of endothelial cell retraction 
(Honn et al, 1991, 1994) .
Several other mechanisms have been proposed to 
explain the enhancement of metastasis by platelets. 
Electron microscopy studies demonstrate that platelets 
are not involved in the initial arrest of tumour cells 
in the microcirculation (Crissman et al, 1985, 1988) .
It has been suggested that they may be more important 
in subsequent stabilization of tumour cell-endothelial 
adhesion. Platelet-derived factors capable of inducing 
the expression of receptors involved in tumour cell 
adhesion to endothelium have been demonstrated 
(Hawrylowicz et al, 1991; Chopra et al, 1991). In 
addition, it has been postulated that platelets may 
physically shield tumour cells within a protective 
platelet cocoon enabling them to escape immune 
surveillance (Dvorak et al, 1979; Gasic et al, 1986), 
encourage tumour survival by providing growth factors 
(Eastment et al, 1987; Poggi et al, 1988) or enhance 
tumour cell adhesion to extracellular matrix (Menter et 
al, 1987) .
The experimental observations reviewed above led 
many workers to conclude that antiplatelet therapy 
might inhibit the development of metastatic disease. 
The results in animal models have been variable and
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while some studies have reported success with cyclo- 
oxygenase inhibitors (Gasic et al, 1973; Kolenich et 
al, 1972; Pollard et al, 1981) and phosphodiesterase 
inhibitors (Gastpar, 1977; Gordon et al, 1979b) others 
have failed to show any such effect (Wood and Hilgard, 
1972; Hilgard et al, 1976) .
In summary, platelets like fibrin, are an 
integral component of tumour emboli that arrest in the 
microcirculation. In animals the ability of tumour 
cells to aggregate platelets in vitro correlates with 
metastatic potential in vivo. Platelet interaction with 
tumour cells involves two general types of mediators: 
membrane-bound molecules (adhesion molecules) and 
soluble release products (predominately arachidonic 
acid metabolites). Platelets may contribute to 
metastasis by stabilizing tumour cell arrest in the 
vasculature. In animals the antimetastatic effect of 
antiplatelet agents is inconsistent and the clinical 
significance is as yet unclear.
3.6 Cinical application of anticoagulant and 
antiplatelet therapy
Pharmacological intervention aimed at modulation of 
coagulation or platelet activation have been shown to 
be capable of reducing metastasis in some animal 
experimental models (Donati et al, 1981; Zacharski et 
al, 1979, 1982; Yano, 1993). Early clinical trials
reporting the application of such treatments in human
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malignancy were less convincing and in general were 
anecdotal pilot studies or at best poorly designed 
clinical trials (Zacharski, 1981) . More recently, 
prolonged survival has been demonstrated by treatment 
with the phosphodiesterase inhibitor RA-233, in non­
small cell lung cancer (Schneider et al, 1987). Two 
prospective randomized trials of warfarin and one of 
heparin have shown significant improvement in tumour 
response rates and overall survival in patients with 
small cell carcinoma of the lung (SCCL) (Chahinian et 
al, 1989; Zacharski et al, 1984; Lebeau et al, 1991). 
Furthermore, pilot studies with combination 
chemotherapy and urokinase have shown enhanced survival 
of patients with disseminated SCCL in comparison with 
chemotherapy alone (Calvo et al, 1992). While these 
studies indicate a role for peritumoural fibrin in 
tumour progression, many tumour types are unresponsive 
to anticoagulant therapy (Zacharski et al, 1990) . By 
contrast several of these tumours, including non-small 
cell lung cancer and ovarian cancer, respond to 
treatment with the protease inhibitor tranexamic acid 
(Astedt, 1980; Kikuchi et al, 1986; Serdengecti et al,
1988) . This suggests the existence of a tumour- 
associated urokinase-initiated protease pathway in 
certain human tumour types.
In summary, the heterogeneity of responsiveness 
to anticoagulant and fibrinolytic agents may be 
attributable to differences in the mechanisms of 
interactions of different tumours with the haemostatic
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system. The role of antiplatelet agents in the 
inhibition of metastasis remains to be defined.
3.7 Summary and role of future studies
Haemostasis and Cancer
It is evident from clinical and animal studies that 
malignant disease activates both the coagulation system 
and platelets. Clinical or subclinical disruption of 
the normal haemostatic balance in favour of a 
hypercoagulable state correlates with disease
progression. Fibrin is an important component of the 
malignant process and influences both primary tumour 
growth and metastasis. The presence of fibrin around 
primary neoplasms is well documented and while it may 
enhance primary tumour growth and reduce malignant cell 
shedding these effects remain to be clarified. The 
role of fibrin and platelets in the metastatic process 
is more convincing and considerable evidence from 
microscopy studies demonstrates that they form 
aggregates with circulating tumour cells within the 
microcirculation.
The importance of fibrin and platelets in the 
intravascular phase of the metastatic pathway has been 
confirmed by demonstration of the antimetastatic effect 
of anticoagulant therapy in several animal models. In 
particular, the coumarin group of anticoagulants has 
been shown to reduce pulmonary tumour seeding of
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intravenously injected tumour cells (Agostino et al, 
1966; Ryan et al, 1969). Microscopy studies by Wood 
(1974) established that the anticoagulant effect was 
associated with the loss of the fibrin/platelet 
thrombus surrounding tumour cells adherent to vascular 
endothelium. Similar antimetastatic effects were 
demonstrated for heparin (Koike, 1964; Hilgard, 1979) 
and the defibrinating agent Arvin (Wood and Hilgard, 
1973). Thus, it has been postulated that anticoagulants 
interfere with the mechanism of metastasis by 
inhibiting clot formation around tumour cells adherent 
to vascular endothelium (Brown, 1973).
Other workers have suggested that the reduction 
in metastasis by coumarin anticoagulation might be due 
to a cytotoxic or cytostatic effect (Ryan et al, 1968b; 
Ryan, 1969; Hilgard et al, 1977). While some studies 
have demonstrated such an effect (Lisnell and Melgrin, 
1963 ; Kirsch et al, 1974), the majority have shown 
little or no reduction in cell viability or rate of 
division (Brown, 1973; Dolfini et al, 1980; McNeil and 
Morgan, 1984) . Recently, in a rat model of 
metastasising breast carcinoma, McCulloch and George 
(1987) confirmed that warfarin inhibits the development 
of pulmonary metastasis. This effect was not associated 
with an alteration in the metabolic activity of tumour 
cells. Furthermore, the administration of the warfarin- 
dependent factor complex II, IX and X enhanced 
pulmonary tumour seeding in a similar model (McCulloch 
and George, 1988). Further studies using radiolabelled
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tumour cells showed that this effect of pulmonary 
tumour enhancement was associated with increased
entrapment of tumour cells in the pulmonary
microcirculation (Purushotham et al, 1991). Elevation 
of fibrinopeptide A levels after inoculation of factor 
complex and tumour cells suggested that this effect was 
due to activation of coagulation (Purushotham et al, 
unpublished data). These findings have led to the 
hypothesis that tumour enhancement by coagulation
factor complex is the result of increased entrapment of 
tumour cells in the microcirculation within a fibrin 
clot. It was therefore postulated that fibrinolytic 
therapy might prevent tumour cell entrapment in the 
microcirculation by dissolution of this fibrin clot, 
thereby inhibiting metastasis.
Preliminary studies have demonstrated a significant 
reduction in the metastatic potential of circulating 
tumour cells after the intravenous administration of 
the fibrinolytic agent Streptokinase (Purushotham et 
al, 1994). The mechanism by which Streptokinase 
produces tumour inhibition requires further 
investigation.
The aim of this study therefore is to investigate the 
mechanism of Streptokinase-mediated tumour inhibition 
in a similar animal model. The following questions 
require to be answered:
1 Does intravenous Streptokinase inhibit pulmonary 
tumour seeding by fibrin clot lysis?
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The observed effect of tumour inhibition by 
Streptokinase in this animal model may be directly 
related to its fibrinolytic properties. It is proposed 
to investigate whether administration of intravenous 
Streptokinase is associated with fibrin clot lysis.
2 Do other clot-lysing agents inhibit pulmonary tumour 
seeding?
If the inhibition of pulmonary tumour seeding by 
Streptokinase is associated with fibrinolysis, then it 
is likely that other clot lysing agents may also be 
antimetastatic. Confirmation that a structurally 
unrelated fibrinolytic agent has a similar effect on 
pulmonary tumour seeding will further confirm the 
mechanism by which fibrinolytic agents inhibit 
metastases.
3 Does antiplatelet therapy enhance inhibition of 
pulmonary tumour seeding by Streptokinase?
Platelets also play a role in the intravascular phase 
of metastasis. It is possible that a dual assault on 
the fibrin and platelet components of tumour
microthrombi in the microcirculation might prove to be 
effective antimetastatic treatment. It is proposed that 
a comparison of pulmonary tumour inhibition of 
antiplatelet and fibrinolytic agents be made.
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3.8 Clinical application of fibrinolytic therapy
The development of an antimetastatic treatment in an 
animal model is only relevant if there is evidence for 
clinical application in patients with cancer. Previous 
work by White et al (197 6) using urokinase to 
facilitate fibrinolysis in human cancer suggests that 
prevention of implantation of circulating malignant 
cells onto vascular endothelium is likely to improve 
patient survival. Fibrinolytic therapy might therefore 
be beneficial if administered to patients at risk of 
haematogenous dissemination from primary tumours.
The inefficiency of the metastatic process 
suggests that spontaneous haematogenous shedding from 
primary tumours rarely leads to metastasis (Weiss, 
1986) . However, the number of metastasis is directly 
proportional to the number of circulating tumour cells 
(Fidler, 1973) and therefore any manipulative
procedure which facilitates primary tumour cell 
shedding into the blood may promote metastasis. 
Fibrinolytic therapy is most likely to be effective in 
preventing metastases if administered during tumour 
cell dissemination. The second half of this thesis is 
designed to investigate whether operative manipulation 
of malignant tumours promotes tumour cell dissemination 
via the bloodstream and whether fibrinolytic therapy 
has a peri-operative role in reducing metastatic 
progression in patients with cancer.
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SURGERY AND METASTASIS
4.1 Evidence for tumour dissemination by surgical 
trauma
Tyzzer (1913) demonstrated that manipulation of 
transplanted breast tumours increased the number of 
pulmonary metastases in mice. He postulated that this 
effect was the result of cell shedding from the primary 
tumour. Ide (193 9) provided microscopic evidence to 
show that tumour manipulation could traumatise friable 
blood vessels and enable individual tumour cells or 
tumour fragments to enter the circulation. Cytological 
studies of the tumour venous effluent in various animal 
models also demonstrated at least a tenfold increase in 
cell shedding during tumour manipulation (Cliffton and 
Agostino, 1960; Romsdahl, 1965; Gazet, 1966; Liotta, 
1974, 197 6). These findings suggest that manipulation
of malignant neoplasms during surgical resection may 
also promote tumour cell dissemination, but evidence in 
support of this hypothesis in patients with malignancy 
is less clear.
In 1934 Pool and Dunlop demonstrated a 
"hitherto undescribed cell" in the peripheral blood of 
17 of 40 patients with advanced malignancy but they 
were unwilling to label these cells as malignant. 
Later, Engell (1955) demonstrated what he deemed to be 
tumour cells in the venous blood draining carcinomas
60
in 59% of patients during surgery, in 13% of peripheral 
blood samples during surgery and in 50% of peripheral 
blood samples in patients with inoperable cancer. Five 
to ten year survival rates were not significantly worse 
in patients noted to have tumour cells in the
bloodstream at the time of surgery. Following these
pioneering studies many attempts were made to estimate 
circulating tumour cells but the results varied widely 
due to problems associated with tumour cell isolation 
and identification (Goldblatt and Nadel, 1965). In the 
case of advanced, inoperable breast cancer, for
instance, the incidence of circulating malignant cells 
varied from 23 to 66% (Moore et al, 1957; Long et al, 
1960; Landell et al, 1963). The morphological
characteristics of malignancy known from cytological 
studies, including increased nuclear cytoplasmic ratio, 
irregular large nucleoli, nuclear hyperchomatism and 
irregularity of the nuclear membrane were open to 
misinterpretation. Many cell types present in the blood 
of patients without malignant disease, including 
megakaryocytes, large myeloid cells and mononuclear 
cells were often confused with tumour cells (Landell et 
al, 1963; Goldblatt and Nadel, 1965) leading to an 
overestimation of tumour cell numbers. In addition, 
many of these studies utilized peripheral venous 
samples which may have underestimated the number of 
tumour cells shed since the vast majority would have 
been removed from the circulation on first passage 
through the microcirculation of a target organ.
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Despite the unreliability of the techniques 
adopted, a few studies attempted to correlate the 
presence of tumour cells in the bloodstream peri- 
operatively with long term survival. The results were 
inconsistent and while some studies demonstrated 
reduced survival rates for patients with tumour cells 
circulating at the time of surgery (Roberts et al, 
1956; Watne et al, 1961), others failed to show any 
such effect (Engell, 1955; Glaves et al, 1988) .
The discovery of monoclonal antibodies (Kohler 
and Milstein, 1975) and the subsequent development of 
immunocytology led to a significant improvement in the 
sensitivity and specificity with which circulating 
tumour cells could be identified in the bloodstream. 
Using a fluorochrome-labelled anticytokeratin antibody 
and indirect immunofluorescence, Glaves (1988) reported 
the presence of epithelial cells in the renal vein of 
patients undergoing nephrectomy for renal 
adenocarcinoma. However, no reduction in disease-free 
survival was demonstrable in patients noted to have 
epithelial cells shed during surgery, although the 
malignant nature of these cells was not confirmed by 
comparison with patients undergoing nephrectomy for 
benign disease. In addition, patient follow-up was 
limited to less than three years. More recently, 
combined immunocytochemistry and conventional cytology 
has been used to establish the malignant nature of 
epithelial cells circulating in the bloodstream of 
patients with colorectal cancer in the peri-operative
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period (Leather et al, 1993). Tumour cells were 
identified in only 4 of 42 patients and no significant 
association was demonstrated with operative
manipulation. However, a preliminary assessment of the 
sensitivity of the tumour cell separation/staining 
technique was made using a homogeneous tumour cell
line. Since primary tumour cells are phenotypically 
more heterogeneous, it is highly likely that their 
behaviour during both density gradient centrifugation 
and immunocytochemical staining would be more variable. 
Therefore the low incidence of operative tumour cell
shedding found in this study may reflect the 
insensitivity of the technique to detect circulating 
primary tumour cells.
Evidence that intra-operative tumour cell
shedding may enhance the metastatic process has been 
provided by the studies of Turnbull (1967) . The
presence of atypical cells in the portal venous blood 
of resected cancer- bearing segments of colon (Cole et 
al, 1954; Fisher and Turnbull, 1955) led Turnbull to 
advocate a technique for the resection of colorectal 
tumours wherein the cancer bearing segment was not 
manipulated until the lymphovascular pedicle and colon 
had been divided. This "no-touch" isolation technique 
was based on the principle of preventing tumour cell 
shedding into the portal circulation at the time of 
tumour manipulation during surgery. The long term 
survival for patients thus treated was significantly 
better than those treated by conventional resection
63
(Turnbull, 1967). Critics attributed these results to 
patient selection and the introduction of a new staging 
system and similar survival rates were claimed for 
extended resection only (Stearns et al, 1971; Enker et 
al, 1979). More recently, a study comparing the "no- 
touch" isolation technique with conventional resection 
has demonstrated a tendency towards a reduction in 
hepatic metastases at five years in the "no-touch" 
isolation group although this did not reach statistical 
significance (Wiggers et al, 1988). Thus the hypothesis 
that intra-operative tumour manipulation encourages 
tumour cell dissemination, thereby facilitating 
metastasis remains unproven and requires further 
investigation.
4.2 The role of surgical stress
There is some experimental evidence from studies in 
animal models that enhanced tumour growth can occur 
following surgery unrelated to the primary tumour 
(Buinauskas et al, 1958; Lewis et al, 1958), and also 
after the administration of specific anaesthetic agents 
(Griffiths et al, 1961; Duncan et al, 1977; Pollard et 
al, 1977). It is believed that the stress of 
anaesthesia and surgery can disrupt the host-tumour 
relationship in favour of tumour growth and 
considerable evidence suggests that this is due to 
suppression of host immune defence mechanisms (Slade et 
al, 1975; Roth and Golub, 1976; Tarpley et al, 1977).
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Circulating numbers of all T lymphocyte subpopulations 
fall during surgery (Lennard et al, 1985) and natural 
killer (NK) cell activity may be reduced by greater 
than 50 per cent (Uchida et al, 1982; McCulloch and 
MacIntyre, 1993). Furthermore, the magnitude and 
duration of the reduction in cell numbers correlates 
with the degree of surgical trauma (Jubert et al, 1973; 
Lennard et al, 1985) .
Surgical trauma may also contribute to enhanced 
tumour cell survival by facilitating the entry of large 
tumour cell clumps into the bloodstream (Ide, 1939; 
Liotta, 1976). Such multicellular emboli have been 
shown to possess greater metastatic potential (Fidler, 
1973; Liotta, 1976; Glaves, 1983). Finally, the 
association between the haemostatic system and 
metastasis suggests that alteration in the haemostatic 
balance in favour of a hypercoagulable state, which 
occurs during surgery (Kambayashi et al, 1990), may 
enhance the entrapment of circulating tumour cells in 
the microcirculation of target organs.
In summary, the results of these studies suggest 
that surgery may have several roles to play in the 
metastatic process:
1. To increase tumour cell shedding during operative 
manipulation.
2. To enhance the survival of circulating tumour cells 
by inducing a state of relative immune suppression.
3. To shield tumour cells within multicellular emboli 
thereby preventing detection by the immune system.
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4. To facilitate the seeding of tumour cells in target 
organs by inducing a more fertile, hypercoagulable 
blood environment.
The relative importance of each of these various 
processes in the human situation is as yet unclear.
4.3 Summary and statement of hypothesis
The studies of Turnbull (1967) using the "no-touch" 
isolation technique have provided the only evidence 
that manipulation of malignant tumours during surgical 
resection may facilitate metastasis. It remains to be 
established whether intra-operative, haematogenous 
tumour cell dissemination represents a significant 
prognostic factor in patients undergoing "curative" 
resection of a primary malignant tumour.
Ninety five per cent of patients who present 
with breast cancer have local disease only, on staging 
by conventional methods (Coombes et al, 1980). However, 
up to a quarter of these patients develop distant 
metastases within 10 years (Valagussa et al, 1978) and 
despite considerable improvements in surgical treatment 
and adjuvant therapy, survival rates have remained 
relatively unchanged. The advent of immunocytochemistry 
has greatly enhanced the ability to detect small foci 
of tumour cells and recent studies have reported bone 
marrow micrometastases in 16-35% of breast cancer 
patients undetected by conventional haematological 
techniques (Cote et al, 1988; Ellis et al, 1989;
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Salvadori et al, 1990) . It would seem therefore that a 
proportion of patients with apparent local disease who 
develop distant metastases may have occult 
micrometastases undetected at initial presentation. 
However, it may also be hypothesized that some 
patients develop metastatic disease as a result of 
malignant cell shedding during surgical resection of 
the primary lesion. Confirmation of tumour cells in the 
circulation peri-operatively would indicate a role for 
peri-operative adjuvant therapy.
The results of adjuvant therapy in patients with 
early breast cancer demonstrate that systemic 
chemotherapy with multiple agents increases overall 
survival and disease-free survival. In addition 
significant benefit has been shown for peri-operative 
chemotherapy and has the potential added advantage of a 
dual assault on circulating tumour cells and 
established micrometastases (Early Breast Cancer 
Trialists Collaborative Group, 1992). However, adjuvant 
therapy is not without risk and in particular 
chemotherapy is associated with a significant incidence 
of systemic toxicity (Early Breast Cancer Trialists 
Collaborative Group, 1992) while fibrinolytic therapy 
may theoretically increase the risk of peri-operative 
haemorrhage. It would therefore seem difficult to 
justify such therapy in all patients undergoing 
"curative" resection in whom the majority would not 
develop metastatic disease. Confirmation of peri­
operative tumour cell shedding would identify patients
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who might benefit from such therapy. Conversely, if it 
were shown that surgery did not enhance tumour cell 
dissemination via the bloodstream then the relevance of 
developing an antimetastatic regime would be called 
into question. At present there are no reliable 
estimates of tumour cell dissemination during surgery 
and the role of operative manipulation in the 
metastatic process remains to be defined.
The aim of the second half of this thesis is therefore 
to investigate the role of operative manipulation in 
the metastatic process and to answer the question:
Does surgical manipulation of primary malignant tumours 
enhance tumour cell dissemination via the bloodstream?
It is proposed that blood samples be collected from 
patients with operable breast cancer in the peri­
operative period and that they be analysed for the 
presence of tumour cells using reliable 
immunocytochemical and molecular biological techniques. 
Such a study will potentially identify circulating 
tumour cells and enable correlation of their presence 
or absence with clinico-pathological variables such as 
type of operation, stage of disease and grade of 
malignancy.
The work contained in this thesis is therefore 
divided into two closely related investigations: 
experimental studies using a rat model of metastasising 
breast carcinoma to investigate the effect of
68
fibrinolytic and antiplatelet therapy on metastasis and 
a clinical study of patients with breast cancer to 
address the problem of identifying tumour cells shed 
into the circulation during surgical manipulation of 
the primary tumour.
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CHAPTER 1
VALIDATION OF PREVIOUS WORK AND THE ANIMAL MODEL OF 
METASTATIC CARCINOMA
INTRODUCTION
Animal experimental evidence has been outlined 
suggesting a beneficial effect of fibrinolytic therapy 
on the metastatic process. Purushotham et al (1994) 
have shown that the fibrinolytic agent Streptokinase 
inhibits pulmonary tumour seeding in an animal model of 
metastasis. To investigate the mechanism by which 
fibrinolytic therapy inhibits tumour enhancement, it 
was essential to use a similar animal model in order to 
draw valid comparisons with the results of previous 
workers. It was therefore necessary to initially 
validate the animal model and to subsequently confirm 
the inhibitory effect of intravenous Streptokinase on 
pulmonary tumour seeding. Validation of the tumour 
model was required because phenotypic drift in the 
tumour cell line can occur leading to a variation in 
lung colonizing potential (Neri and Nicolson, 1981). In 
addition, variation in the mechanism of lung 
colonization may produce discrepancies between surface 
tumour deposits and total lung tumour burden.
The tumour model utilized for these experiments 
was the female Fischer 344 rat in combination with the 
Mtln3 clone of the 137 62NF rat mammary carcinoma cell 
line. This animal model was originally chosen as it
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fulfills the following criteria required for comparison 
with human cancer:
1. The tumour should metastasise reliably and 
spontaneously from the primary tumour.
2. It should resemble human carcinoma as closely as 
possible in terms of its histological origin, 
morphology and behaviour.
3. It should be possible to grow the tumour cells in 
vitro.
4. The tumour should be syngeneic with the host animal 
and should not elicit a significant immune response in 
the host.
5. It should be possible to effectively evaluate 
changes in the haemostatic system in the host.
6. Administration of intravenous tumour cells should 
give measurable and reproducible results.
The Mtln3 cell line resembles human breast cancer both 
morphologically and in its propensity to metastasise to 
lung and regional lymph nodes (Neri et al, 1982) . In 
addition, the tumour is syngeneic with the host animal 
and thus does not elicit a significant humoral or 
cellular immune response either after intravenous 
injection or prolonged growth in the host (North and 
Nicolson, 1985) . Finally, the cloned cell line can 
easily be maintained in tissue culture so that in vitro 
assessment of cytotoxicity can be performed.
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Metastatic tumour model.
The animals used in this study were female, Fischer 344 
rats, mean weight 140 grams, between 6-8 weeks old 
(Olac Limited, Bicester, UK). Animals were housed three 
to a cage and fed a standard laboratory diet (CRM diet, 
Labsure, Cambridge, UK) and tap water with a chlorine 
content of 7 mg/ml. All animals were healthy to visual 
inspection and to the results of routine 
microbiological testing.
The tumour cell line utilized in these 
experiments was a clone of rat mammary carcinoma 
designated Mtln3 (Figure 6), and was obtained from 
frozen cultures at the Department of Oncology, 
University of Glasgow. The original clone was derived 
by Neri et al (1982) from the 7, 12-dimethylbenz (a)
anthracene - induced adenocarcinoma 137 62 (Segaloff, 
1966). The cells were cultured in 75 cm2 tissue culture 
flasks (Gibco, Paisley, UK) in equal parts of Hams' F10 
medium and Dulbecco's modified Eagles' medium 
(F10/DMEM), with 10% foetal calf serum (FCS) but 
without antibiotics. Cultures were maintained at 37°C 
in equilibrium with 2% C02 in air. Once cultures were 
confluent passage was carried out by washing with 5 ml 
of trypsin/EDTA (0.2 5%/lmM) and incubated for 5 minutes 
at 37°C. Subcultures required the addition of 2 x 106 
viable tumour cells to further 75 cm2 flasks. Cells 
were passaged a maximum of 6 times between thawing and 
use to minimize the problems of phenotypic drift and
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F i g u r e  6 Morphogy of Mtln3 rat mammary carcinoma cells 
in culture (x 625 magnification)
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reduction in metastatic potential (Neri and Nicolson, 
1981). Mycoplasma contamination of cultures was 
excluded by monthly testing with Hoechst stain 33258.
For the purpose of these studies, tumour cells 
were prepared for inoculation by trypsinisation, washed 
twice in F10/DMEM by centrifugation at 200g for 5 
minutes, and finally resuspensed in F10/DMEM. Cells 
were then counted on a Neubauer haemocytometer and 
resuspended in F10/DMEM at a concentration of 105 cells 
per 0.5ml of medium. Animals were inoculated 
intravenously by tail vein injection under general 
anaesthesia with intraperitoneal pentobarbitone 
(60mg/kg).
Validation of Method for Identifying Pulmonary 
Metastases
An estimation of pulmonary seeding by serial 
histological section is time consuming and 
inappropriate for studies which necessarily involve 
large numbers of experimental animals. Wexler (1966) 
described a relatively simple and reliable method for 
the accurate enumeration of pulmonary tumour nodule 
formation in other models of metastasis. This well 
validated technique involves insufflation of the lungs 
via the trachea with 15% India ink in distilled water. 
The lungs are then excised and immersed for 48 hours in 
Fekete's bleaching solution (alcohol, acetic acid and 
formaldehyde). Pulmonary metastases appear as white
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nodules on a black background (Figure 7). The weight of 
the lungs was used to assess whether surface tumour 
deposits detected by this method accurately reflected 
total lung tumour burden.
A pilot study was performed to validate:
a. the dose of Mtln3 cells used in previous 
experiments (105)
b. the optimum time of sacrifice after tumour cell 
injection (17 days)
c. Wexler's method
(McCulloch & George, 1987)
EXPERIMENT
Eight female Fischer 344 rats, 6-8 weeks old, were 
inoculated by tail vein injection with 105 Mtln3 tumour 
cells in 0.5ml of F10/DMEM, under general anaesthesia. 
Animals were sacrificed at 17 days after injection and 
lungs excised and weighed. Surface pulmonary tumour 
nodules were assessed by the method of Wexler. 
Statistical correlation between the number of pulmonary 
tumour nodules and the weight of the lungs was made by 
Spearman's rank correlation test.
RESULTS
Table 1 shows the weight of lungs, expressed as 
percentage of body weight, and the number of pulmonary 
tumour nodules detected by the method of Wexler.
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F i g u r e  7 Rat lungs showing subpleural tumour deposits 
prepared by the method of Wexler
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Table 1
Validation of Wexler's Method
Num ber of 
Pulm onary M etastases
Lung weight
(expressed as % bodyweight)
9 8 0 .7 4
7 5 0 .5 8
8 4 0 .6 0
8 7 0 .6 6
9 0 0 .6 8
9 5 0 .7 0
79 0 .5 9
81 0.61
Spearm an's Rank Correlation Coefficient 0 .9 7
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Statistical analysis demonstrated that there was a 
significant correlation between the weight of the lungs 
and the number of pulmonary tumour deposits as detected 
by Wexler's method (Spearman's rank correlation 
coefficient 0.97).
DISCUSSION
This preliminary study confirmed that this tumour model 
was suitable for the investigation of aspects of the 
metastatic process in an animal model. The intravenous 
administration of 105 Mtln3 tumour cells was associated 
with the formation of well circumscribed, easily 
identifiable, subpleural tumour deposits. In addition, 
the method for pulmonary tumour nodule formation was 
successfully validated. Previous work in 8 other animal 
systems (Wexler, 1966) has shown that excellent 
correlation exists between the number of surface tumour 
nodules detected by this method and the total lung 
tumour burden estimated by more rigorous but laborious 
methods. A discrepancy between the true and estimated 
numbers of pulmonary tumour nodules may arise in three 
ways: tumours may grow in a fashion which prevents
accurate identification and counting; there may be a 
variable relationship between the total lung tumour 
burden and the surface tumour nodules; artefacts may 
arise which indicate the presence of a tumour deposit 
where none exists. These possibilities could be 
discounted in the experiment described above by 
observation of the pattern of tumour growth seen. The
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tumour formed well-circumscribed deposits after 
intravenous injection while the proportion of deposits 
at the pleural surface was consistent, as judged by the 
weighing of lungs for total tumour burden. Artefact 
formation did not appear to be a source of serious 
error as the method of Wexler successfully 
differentiated tumour-bearing from tumour- free lungs. 
Thus the correlation between total pulmonary tumour 
burden as estimated by weighing of lungs, and surface 
tumour deposits indicates that the method of Wexler is 
adequate for estimation of major changes in the lung 
burden of Mtln3 tumour.
Validation of Inhibitory Effect of Streptokinase on 
Pulmonary Tumour Seeding.
The fibrinolytic agent Streptokinase (Hoechst UK Ltd, 
Hounslow, England) was used in this experiment. Fibrin 
clot lysis by Streptokinase involves the activation of 
the intrinsic fibrinolytic system by the formation of a 
linkage compound between Streptokinase and the 
proactivator-plasminogen molecule. This activating 
complex then facilitates the conversion of plasminogen 
into the fibrinolytic enzyme plasmin.
Previous experiments have shown that an 
intravenous injection of Streptokinase in a dose of 30 
000 Units/Kg, 30 minutes after tumour cell inoculation, 
inhibits pulmonary tumour seeding in an animal model.
(Purushotham et al, 1994)
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A pilot study was performed to validate:
a. the dose of Streptokinase previously used (30 000 
Units/kg)
b. the optimum time of administration after tumour cell 
inoculation (30 minutes)
(Purushotham, 1994)
EXPERIMENT
Two groups of ten female Fischer 344 rats 6-8 weeks old 
were used in this experiment. Under general 
anaesthesia, animals were injected intravenously with 
a 0.5ml suspension of 105 Mtln3 cells in F10/DMEM. 
Additional treatment was administered as follows:
Group A: These control animals received no additional 
treatment
Group B: These animals received an intravenous 
inj ection
of Streptokinase 30 minutes after tumour cell injection 
(t=3 0) .
The dose of Streptokinase administered was 30 000
units/kg body weight. This was based on previous animal 
experimental work wherein clot lysis was achieved in 
vivo (Lyden et al, 1990).
Animals were sacrificed after 17 days and pulmonary 
tumour nodules assessed by the method of Wexler. 
Comparison of the two groups was made by the Mann- 
Whitney test.
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RESULTS
Animals that received intravenous Streptokinase and 
tumour cells showed a significant reduction in 
pulmonary tumour seeding (Group B, median = 46.5) when 
compared with control animals that received tumour 
cells alone (Group A, median = 91; p < 0.001) (Figure 
8 ) .
DISCUSSION
The results of this experiment demonstrate that 
Streptokinase produces a significant reduction in 
pulmonary tumour seeding when administered as a bolus 
"clot-lysing" dose of 30 000 Units/kg, 30 minutes after 
tumour cell injection. This confirms the findings of 
Purushotham et al (1994). The time of administration is 
critical and is determined by the pharmacodynamics of 
Streptokinase and the process of intravascular tumour 
cell arrest. Streptokinase has a very short circulating 
half-life (Grierson and Bjorson, 1987) and therefore to 
be effective must be administered at the time of 
intravascular fibrin formation. Previous studies using 
radiolabelled tumour cells have demonstrated that there 
is a sharp rise in the number of cells trapped within 
the pulmonary microcirculation between 3 0 and 60 
minutes after tumour cell injection - the time of 
fibrin clot formation (Purushotham et al, 1991). If 
Streptokinase is administered prior to fibrin clot 
formation, its rapid disappearance from the circulation
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Figure. 8
Effect of Streptokinase on Pulmonary 
Tumour Seeding
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will result in an absence of any effect on subsequent 
fibrin clot formation.
The mechanism of action for Streptokinase in 
this experiment has not been established and while 
drug-related cytotoxicity for the Mtln3 cell line has 
previously been excluded (Purushotham et al, 1994), 
there is no conclusive evidence to demonstrate that its 
antitumour effect is due to fibrinolysis. It is 
possible that Streptokinase inhibits pulmonary tumour 
inhibition via a completely separate mechanism and 
therefore it is important to establish whether this 
effect is secondary to fibrin clot lysis. The 
demonstration of fibrinolysis would indicate the need 
to perform further work to investigate the role of 
other fibrinolytic agents with regard to inhibiting 
tumour metastasis.
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CHAPTER 2
STUDIES TO DETERMINE WHETHER THE INHIBITION OF 
PULMONARY TUMOUR SEEDING BY STREPTOKINASE IS ASSOCIATED 
WITH FIBRIN CLOT LYSIS
INTRODUCTION
Fibrin is an important component of both primary 
malignant tumours and metastases. It can be detected at 
an early stage of tumour growth and is also present 
within the tumour cell stroma throughout tumour growth 
(Dvorak et al, 1984) . Fibrin also enhances the 
metastatic potential of circulating tumour cells by 
forming a latticework around tumour cells trapped 
within the microcirculation of target organs (Crissman, 
1985). This is thought to facilitate the adhesion of 
tumour cells to vascular endothelium by acting as an 
"intercellular" glue (Francis, 1989).
The preceding chapter has demonstrated that 
Streptokinase can reduce the efficiency of the 
metastatic process in an animal model. The importance 
of fibrin in the metastatic process would suggest that 
this antimetastatic effect may be due to fibrin clot 
lysis but conclusive evidence of an association between 
fibrin and tumour cells within the microvasculature has 
not been demonstrated in this model. It is therefore 
possible that the reduction in pulmonary tumour seeding 
by Streptokinase in this model may be secondary to a 
completely different mechanism. Confirmation of 
fibrinolysis would provide further evidence supporting
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an involvement of the coagulation system in the 
metastatic process.
Fibrin and fibrinogen are progressively split by 
the enzyme plasmin into a heterogeneous mixture of 
small peptides known collectively as fibrin(ogen) 
degradation products (FDP). Plasmin attacks at least 50 
cleavage sites in fibrinogen and eventually leads to 
the release of fragments Y, D and E which can be 
detected immunologically using a latex agglutination 
assay. For the purpose of our experiment, fibrin clot 
breakdown was assessed by estimation of plasma FDP by 
this technique.
MATERIALS AND METHODS
Measurement of Plasma FDP
Method of blood collection
In preliminary pilot studies, blood samples were 
obtained by direct puncture of the abdominal aorta but 
this technique was found to be unsatisfactory as the 
trauma of laparotomy was sufficient to activate 
coagulation and elevate plasma FDP levels. Subsequent 
studies demonstrated that the less traumatic procedure 
of direct cardiac puncture was associated with a much 
lower level of inappropriate activation of coagulation. 
In addition, in order to minimise the risk of sample 
clotting, blood was collected into citrate-treated 
syringes and rapidly transferred to plastic bottles
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containing 6% sodium citrate in a ratio of 9:1 v/v. 
Plasma was prepared by centrifugation of blood samples 
at 3 000 g for 15 minutes at a temperature of 4° C. The 
fresh rat plasma thus obtained was snap-frozen and 
stored at -70°C prior to analysis for FDP.
Time of sampling
The time interval was determined by a pilot study 
whereby animals (3 per group) were exsanguinated at 10, 
30, 40 and 60 minutes after Streptokinase therapy.
Analysis of FDP levels established that maximum fibrin 
breakdown occured at 10 minutes (Table 2).
Method of analysis
Plasma FDP levels were determined using a latex 
agglutination kit (Diagnostica Stago, Asnieres-Sur- 
Seine, France). In the presence of the corresponding 
antigens, the latex particles coated with anti-FDP 
antibody form macroscopic clumps. A 20 ul plasma sample 
was mixed with 20 ul of a solution of latex particles 
coated with mouse monoclonal anti-human FDP antibodies. 
The presence of agglutination was assessed by 
comparison with a positive control (20 ul plasma + 20 
ul FDP solution) and a negative control (20 ul plasma + 
20 ul FDP-free solution). Serial dilution of plasma 
with glycine buffer enabled semi-quantitative analysis 
of FDP levels.
Table 2
Effect of Intravenous Streptokinase 
on FDP Levels
Tim e after 
Streptokinase  
therapy  
(M inutes)
FD P
level
(pg/ml)
10 > 120
30 5 - 2 0
40 < 5
60 < 5
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EXPERIMENT
Three groups of 10 female Fischer F344 rats, 6-8 weeks 
old were used for this experiment. All animals received 
a tail vein injection of 105 Mtln3 tumour cells in 
0.5ml of F10/DMEM, under general anaesthesia. 
Additional treatment was administered as follows:
Group A: These control animals received no additional
treatment.
Group B: These animals received an injection of 0.5 ml 
normal saline 3 0 minutes after tumour cell inoculation. 
Group C: These animals received an injection of
Streptokinase (30 000 U/kg) in 0.5ml normal saline 30 
minutes after tumour cell inoculation.
Time of blood sampling
Blood samples were taken 10 minutes after the
administration of normal saline or Streptokinase. 
Samples were then prepared and analysed for FDP
estimation as previously described.
RESULTS
Semi-quantitative analysis of plasma FDP demonstrated 
that 6 of 10 animals that received Streptokinase (60%) 
had FDP levels > 12 0 ug/ml in comparison with 3 of 10 
animals in both control groups (30%) (Figure 9).
Statistical analysis by rank testing demonstrated that
although there was a trend towards increased FDP
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Figure 9
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production in animals that received Streptokinase, this 
was not statistically significant (p=0.061).
DISCUSSION
The role of fibrin in the metastatic process suggests 
that the inhibition of pulmonary tumour seeding by 
Streptokinase might be secondary to fibrinolysis. This 
experiment has however failed to demonstrate evidence 
of significant fibrin breakdown with Streptokinase 
therapy. Information from this experiment provided us 
only with an index of activity of the fibrinolytic 
system at one fixed point in time. The preliminary 
studies suggested that the most suitable time of 
sampling blood for assay of FDP was 10 minutes after 
administration of Streptokinase. Estimated FDP values 
however showed wide variation within the same 
experimental group. This may partly be explained by the 
tendency for rat plasma to clot spontaneously despite 
atraumatic blood collection and adequate 
anticoagulation (Lewis et al, 1985). FDP levels reflect 
activity in either the coagulation or fibrinolytic 
system and their presence in control samples was 
presumably the result of low grade activation of 
coagulation. As a result, a significant rise in FDP in 
the Streptokinase group may have been masked by the 
detectable FDP levels in controls.
It could also be argued that latex agglutination 
lacks the sensitivity required to detect the changes in
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haemostatic balance which occur in association with the 
metastatic process. McCulloch and George (1988) have 
shown, that in a similar tumour/host system, the 
administration of Arvin, a defibrinating agent, could 
reduce the fibrinogen level by nearly 7 0% but had no 
effect on metastasis formation. This suggests that the 
amount of fibrin required to form tumour microthrombi 
may be small and therefore insufficient to produce a 
marked rise in FDP during fibrinolysis.
Finally, it is possible that the antimetastatic 
effect of Streptokinase may not be associated with 
fibrin clot lysis. If this is the case then it is 
unlikely that a second fibrinolytic agent, unrelated 
to Streptokinase, will also inhibit metastasis unless 
there is a shared mechanism involving fibrinolysis. 
Human recombinant tissue plasminogen activator (rt-PA) 
is frequently used for thrombolytic therapy in humans 
and would seem an appropriate agent for comparison 
with Streptokinase. Confirmation of a similar 
antitumour effect by rt-PA in a similar animal model 
will add weight to the evidence that the antimetastatic 
effect of Streptokinase is secondary to clot lysis.
91
CHAPTER 3
INHIBITION OF PULMONARY TUMOUR SEEDING BY FIBRINOLYTIC 
THERAPY: A COMPARISON OF STREPTOKINASE AND HUMAN
RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR.
INTRODUCTION
The studies thus far have provided evidence in support 
of the hypothesis that intravascular fibrin clot 
formation contributes to the metastatic process. It has 
been shown that administration of Streptokinase is 
associated with a reduction in metastatic potential of 
circulating tumour cells. In addition, elevated FDP 
levels during Streptokinase therapy suggest that the 
antitumour effect may be due to fibrin clot lysis. The 
demonstration that another clot lysing agent, 
structurally unrelated to Streptokinase could also 
reduce pulmonary tumour seeding would add further 
evidence to the above hypothesis. An experiment was 
therefore designed to study the effect of a second 
fibrinolytic agent on pulmonary tumour seeding.
The fibrinolytic agent chosen for comparison 
with Streptokinase was human recombinant tissue 
Plasminogen Activator (rt-PA) (Boehringer Ingelheim, 
Ingelheim, FRG) . Evidence from randomized controlled 
trials using fibrinolytic therapy for coronary 
recanalization during myocardial infarction indicate 
that rt-PA is a more efficient thrombolytic agent than 
Streptokinase (Verstraete et al, 1985; Chesebro et al, 
1987; Chesebro et al, 1988). In addition, the
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fibrinolytic process induced by rt-PA is relatively 
fibrin-specific and causes only limited systemic 
plasminogen activation and fibrinolysis.
Preliminary in vitro studies were initially 
performed to establish whether rt-PA was cytotoxic for 
the Mtln3 tumour cell line. Subsequently, a further 
experiment was performed to compare the effects of 
intravenous Streptokinase and rt-PA on pulmonary tumour 
seeding.
EXPERIMENT 1
In Vitro Assessment of Cytotoxicity*
No single in vitro test is an ideal measurement of 
cytotoxicity and each measures a different aspect of 
the balance between cell division and cell death. For 
this reason two complementary in vitro techniques were 
used to determine the cytotoxicity of rt-PA for the 
Mtln3 cell line. The clonogenic assay assesses the 
ability of tumour cells to survive and multiply to form 
individual colonies. It is therefore affected by 
cytotoxic effects which kill cells and cytostatic 
effects which inhibit multiplication. The 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide 
(MTT) assay is a chemosensitive assay which is used to 
estimate surviving cell numbers following exposure to a 
cytotoxic drug (Plumb et al, 1989). It is influenced by 
the rate of cell division and the rate of cell death. 
The assay relies on the ability of live but not dead
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cells to reduce the water-soluble yellow dye MTT, to a 
water-insoluble purple formazan product. MTT-formazan 
production is measured by spectral analysis at 570 nm 
and if the MTT concentration is optimal, a linear 
relationship exists between cell number and MTT- 
formazan production.
Clonogenic Assay
Mtln3 cells were cultured in F10/DMEM with 10% FCS. 
Cells were then trypsinised, incubated for 5 minutes at 
37° C, resuspended in 10 ml medium and plated out at a 
concentration of 106 cells per 25 cm2 flask (Gibco, 
Paisley, Scotland) . Cells were then incubated in 5mls 
F10/DMEM + 10% FCS at 37° C in equilibrium with 2% C02 
in air for 2 days. The medium was removed and flasks 
fed with 5 mis of medium or medium containing drug and 
incubated for 4 hours. The medium was then removed and 
the cells trypsinised and resuspended in 10 mis medium 
at a concentration of 100 cells per ml. Five mis (500 
cells) were plated out into each of four Petri dishes 
(60 cm Nunclon; Gibco, Paisley, Scotland) and incubated 
at 37°C in equilibrium with 2% C02 in air for 7 days. 
The medium was then removed and clones washed with PBS, 
fixed in methanol and stained with crystal violet. 
Colonies of greater than 50 cells were counted.
The dose of rt-PA and Streptokinase added to flasks (4 
flasks per dose) ranged from 0.05 mgs/ml to 1 mg/ml of 
medium for rt-PA and 250 Units/ml to 5000 Units/ml for 
Streptokinase.
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These concentrations were determined from an estimation 
of the expected plasma concentration of rt-PA and 
Streptokinase in the experiment. These estimates were 
based on knowledge of the size of the vascular 
compartment in rats. Previous studies have shown the 
blood volume of the rat to be 5.75 - 8.4 ml/100 gm body 
weight (Huang and Bondurant, 1956; Jorgenson et al, 
1958; Ormond and Rivera-Velez, 1965). Since the mean
weight of rats in this experiment was 150 gms the 
approximate blood volume was 12.6 mis (8.4% body 
weight, Ormond and Rivera-Velez, 1965). Since the mean 
pack cell volume of a rat is 35% (Lewis et al, 1985) 
the plasma volume for a rat weighing 150 gms is 8.19 
mis (65% of 12.6 mis). The dose of drug administered to 
animals was 5 mgs/kg for rt-PA and 30 000 Units/kg for 
Streptokinase. For animals weighing 150 gms this 
represents a dose per animal of 0.75mgs of rt-PA and 
4500 Units of Streptokinase. Therefore the peak plasma 
concentration for rt-PA would be 0.092 mgs/ml 
(0.75mgs/8.19mls) and for Streptokinase would be 549 
units/ml (4500 Units/8.19mls).
RESULTS
The mean number of colonies in the experimental groups 
exposed to Streptokinase ranged from 195-212, with 208 
colonies in the control group (Table 3). Streptokinase 
did not exhibit any cytotoxic or cytostatic effect on 
Mtln3 cells.
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The mean number of colonies in the experimental 
groups exposed to rt-PA at concentrations below 0.5
mg/ml ranged from 190-202, with 191 colonies in the 
control group. At a concentration of 1 mg/ml the mean 
number of colonies was significantly reduced in 
comparison with controls (117 vs 191, p < 0.001). rt-PA 
had no inhibitory effect on the clonogenic potential of 
Mtln3 cells at concentrations below 0.5 mg/ml.
MTT Assay
Mtln3 cells were trypsinised and prepared as above and 
plated out in 200 ul of F10/DMEM + 10% FCS at a
concentration of 500 cells per flat-bottomed well in 
96-well microtiter plates (Linbro; Flow Laboratories, 
Irvine, Scotland). The first and last 8 wells contained 
medium only. Plates were incubated at 37°C in 
equilibrium with 2% C02 in air for 2 days. The medium 
was then removed from the wells and replaced with 2 00 
ul of fresh medium or medium containing drug (8 wells 
per concentration) . Cells were incubated for 4 hours 
after which medium was replaced by drug-free medium. 
The medium was replaced at 24 hour intervals for a
further 2 days. On the fourth day following drug 
addition, medium was replaced and 50 ul of MTT 
dissolved in PBS (5 mg/ml) was added to each well. 
Plates were wrapped in aluminium foil and incubated for 
a further 4 hours. Medium and MTT were removed from the 
wells and the formazan crystals were dissolved in 200 
ul of dimethyl sulphoxide (DMSO) . Finally, 25 ul of
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Sorensen's glycine buffer (0.1M glycine plus 0 . 1M NaCl 
equilibrated to pH 10.5 with 0. 1M NaOH) was added to 
each well. The absorbance was recorded in an enzyme- 
linked immunosorbent assay plate reader (Model 2 550 
enzyme immunoassay plate reader; Bio-Rad Laboratories, 
Ltd., Watford, England) at a wavelength of 570 nm. The 
first and last rows of 8 wells which contained medium 
and PBS (50 ul) only were used to blank the plate 
reader. The following drug concentrations were used: 
rt-PA - 0, 0.01, 0.05, 0.1, 0.2, 0.4, 0.6, 0.8 and 1.0 
mgs/ml
Streptokinase - 0, 100, 250, 500, 750, 1500, 3000, 4000 
and 5000 Units/ml
RESULTS
Spectral absorbance at 570 nm ranged from 2.72-2.75 for 
rt-PA (control 2.70) and from 2.71-2.76 for 
Streptokinase (control 2.71). MTT-formazan formation 
was not reduced by exposure to either drug thereby 
indicating that rt-PA and Streptokinase were not 
cytotoxic for the Mtln3 cell line (Table 4).
EXPERIMENT 2
Effects of Streptokinase and rt-PA on pulmonary tumour 
seeding
Three groups of 10 F344 female rats, 6-8 weeks old were 
used in this experiment. Cells were prepared as 
previously described from low-passage in vitro cultures
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Effect of rt-PA and Streptokinase on 
Tumour Cells
T a b le  3
Clonogenic Assay
rt-PA Dose 
(mg/ml)
0 0.05 0.1 0.5 1
Num ber of 
colonies
191
(c)
202 194 190 117
Streptokinase
dose
(units/ml)
0 250 500 2500 5000
Num ber of 
colonies
208
(c)
205 212 197 195
C : Control
T a b le  4
MTT Assay
rt-PA Dose 
(mg/ml)
0 0.01 0.05 0.1 0.2 0.4 0.6 0.8 1.0
Absorbance  
(570 nm)
2.70
(c)
2.73 2.72 2.74 2.72 2.72 2.74 2.75 2.74
Streptokinase
dose
(units/ml)
0 100 250 500 750 1500 3000 4000 5000
Absorbance  
(570 nm)
2.71
(c)
2.74 2.72 2.71 2.74 2.72 2.75 2.76 2.75
C : Control
98
and resuspended in F10/DMEM. Animals received an 
intravenous injection of a 0.5ml suspension of 105 
Mtln3 cells under general anaesthesia (intra-peritoneal 
pentobarbitone 60mgs/kg). Additional treatment was then 
administered as follows:
Group A: No additional treatment (controls).
Group B: A single tail vein injection of rt-PA, in a 
dose of 5mgs per kg body weight, 3 0 minutes after 
tumour cell inoculation.
Group C: A single tail vein injection of Streptokinase, 
in a dose of 30 000 Units per kg body weight, 30
minutes after tumour cell inoculation.
The dose of rt-PA administered was based on previous 
animal experimental work wherein clot lysis was 
achieved in vivo (Lyden, 1990) .
The estimated peak plasma concentrations for rt-PA in a 
dose of 5mgs/kg, and for Streptokinase in a dose of 30 
000 Units/kg, were 0.092 mgs/ml and 549 Units/ml 
respectively (see materials and methods).
Animals were sacrificed at 17 days after tumour cell 
injection and the lungs prepared according to the 
method of Wexler as previously described.
Three animals did not survive the experimental period 
(one in Group B and two in Group C) . Post-mortem
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examination did not reveal any evidence of haemorrhagic 
complications and the cause of death was unknown.
RESULTS
Both Streptokinase and rt-PA caused a significant 
reduction in pulmonary tumour nodule formation (Figure 
10) . The mean number of lung nodules in untreated 
controls was 55 in comparison with 27 in the group 
administered rt-PA (Group A vs Group B, p < 0.001) and 
2 5 in the group administered Streptokinase (Group A vs 
Group C, p < 0.01) . There was no significant difference 
in pulmonary nodule formation between groups treated 
with rt-PA or Streptokinase (Group B vs Group C, p = 
0.56) .
DISCUSSION
The preliminary in vitro studies showed that 
Streptokinase was not cytotoxic or cytostatic for Mtln3 
cells. However rt-PA reduced colony-forming potential 
at high concentration although this was not associated 
with a reduction in cell viability as measured by the 
MTT assay. The sensitivity of the clonogenic assay to 
factors which disrupt the ability of cells to 
proliferate suggests that the reduction in the number 
of colonies may be due to a cytostatic effect. The 
clonogenic assay requires exposure of cells to drug 
before plating and the observed effect may be a 
consequence of cell membrane disruption sufficient to 
reduce surface adherence and proliferation but not to
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Figure 10
Effect of rt-PA and Streptokinase on Pulmonary
Tumour Seeding
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kill cells. It has been assumed that rt-PA disperses 
evenly throughout the intravascular compartment and is 
rapidly cleared from the circulation by hepatic 
degradation (initial half-life < 3 minutes in rats,
Harris et al, 1988). Studies in humans however, have 
shown that fibrin-bound rt-PA may remain 
pharmacologically active at the clot site for several 
hours (Verstraete et al, 1985; Eisenberg et al, 1987). 
Thus, tumour cells trapped within this clot may be 
exposed to higher drug levels than circulating tumour 
cells although it is unlikely that this would exceed 
the concentrations and duration of exposure achieved in 
the in vitro studies.
This experiment has demonstrated that both rt-PA 
and Streptokinase inhibit pulmonary tumour seeding. 
Streptokinase is produced by beta-haemolytic 
streptococci and its mechanism of action involves 
activation of the intrinsic fibrinolytic system. rt-PA 
is produced by bulk fermentation of a Chinese hamster 
ovary cell line transfected with the cDNA for the 
naturally occuring human protease enzyme synthesized by 
the vascular endothelium (Collen et al, 1989) . rt-PA 
has a high affinity and specificity for fibrin-bound 
plasminogen where it causes enzymatic degradation of 
the latter into plasmin and consequently thrombolysis. 
The demonstration that two structurally distinct 
compounds, unrelated except for their ability to induce 
fibrin clot lysis, could inhibit pulmonary tumour
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formation substantiates the role of fibrin in the
metastatic cascade.
In this study both fibrinolytic agents were 
administered as a bolus injection in contrast to the
standard therapeutic regime in man of a loading bolus 
(usually 10% of the total dose) followed by an infusion 
over 3 hours. It could therefore be argued that an
intravenous infusion might be a more effective regimen 
for the reduction of pulmonary tumour seeding in this 
animal model. However, the thrombolytic effect of rt-PA 
has been found to be sustained for up to 7 hours 
following its clearance from the circulation in animal 
models (Agnelli et al, 1985; Clozel et al, 1989) and in 
patients with myocardial infarction (Eisenberg et al,
1987). These observations are consistent with prolonged 
fibrinolytic activity of rt-PA bound to fibrin. This 
suggests that bolus injection may be as effective as 
infusion therapy. Indeed, equivalent efficacy has been 
demonstrated in preliminary experiments with bolus rt- 
PA and infusion in animals (Longridge et al, 1991) and 
patients with acute myocardial infarction (Tebbe et al, 
1989) .
These findings raise interesting questions as to 
whether fibrinolytic therapy can influence the human 
metastatic cascade and thus play a role in the 
treatment of patients with malignancy. rt-PA is the 
more attractive agent for such therapy as it is 
identical to endogenous t-PA and does not elicit an 
immune response. In contrast, Streptokinase is
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antigenic and immunogenic in humans, allergic
reactions occuring in up to 5% of patients. 
Furthermore, anti-Streptokinase antibody can bind to 
platelets and induce platelet activation thereby 
limiting the therapeutic effect (Vaughan et al, 1991) . 
Finally, the fibrin specificity of rt-PA limits 
activation of circulating plasminogen and as a result 
bleeding complications are less frequent than with 
Streptokinase (Verstraete et al, 1985; Magnani et al, 
1989) .
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CHAPTER 4
STUDIES TO DETERMINE WHETHER PULMONARY TUMOUR 
INHIBITION BY FIBRINOLYSIS IS ENHANCED BY ANTIPLATELET 
THERAPY
INTRODUCTION
The preceding chapters have investigated the role of 
fibrin in the metastatic process. The presence of 
platelets within tumour emboli trapped within the 
microcirculation of target organs has also attracted 
considerable attention. Platelets do not appear to 
influence initial tumour cell arrest in the 
microvasculature (Crissman et al, 1985, 1988), rather
they seem to be more important in stabilization of 
tumour cell-endothelial adhesion (Hawrylowicz et al, 
1991; Chopra et al, 1991) . In addition, platelets may 
enhance metastasis by shielding tumour cells from 
immune destruction (Dvorak et al, 1979; Gasic et al, 
1986), by providing growth factors (Eastment et al, 
1987; Poggi et al, 1988), or by facilitating adhesion 
to the extracellular matrix (Menter et al, 1987).
Our previous experiments have suggested that 
destruction of the fibrin element within tumour emboli 
reduces pulmonary tumour seeding. Studies in other 
animal models have shown that antiplatelet agents also 
reduce the metastatic potential of circulating tumour 
cells (Gasic et al, 1973; Kolenich et al, 1972; Pollard 
et al, 1981) . The importance of both fibrin and 
platelets in the metastatic process suggests that the
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combination of fibrinolytic and antiplatelet therapy 
may have an additive inhibitory effect on metastasis. 
In addition, platelets are thought to play a major role 
in reducing the efficiency of thrombolytic therapy. 
They are an important component of thrombi particularly 
at their point of attachment to the vessel wall and 
recent studies have demonstrated that fibrinolytic 
agents cause marked platelet activation (Fitzgerald et 
al, 1988, 1989; Vaughan et al, 1991). Consequently,
antiplatelet therapy has been advocated during coronary 
thrombolysis to enhance vessel patency and the 
combination of Streptokinase and aspirin has been shown 
to be superior to the use of either agent alone (ISIS- 
2, 1988). It would therefore seem appropriate to study
the antimetastatic effect of a combination of 
Streptokinase and antiplatelet agents in this animal 
model to determine whether this combination therapy is 
superior to fibrinolytic therapy alone.
For the purpose of our experiment, we used two 
antiplatelet agents with completely separate mechanisms 
of action. Aspirin (acetyl salicylic acid) causes 
irreversible acetylation of the enzyme cyclo-oxygenase, 
leading to a reduction in the synthesis of 
prostaglandins derived from arachidonic acid. At low 
dose, aspirin preferentially inhibits the synthesis of 
the prostaglandin Thromboxane A2 (TXA2), a potent 
platelet aggregator and vasoconstrictor. Ticlopidine (a 
thienopyridine derivative) inhibits ADP-induced 
platelet aggregation and although the precise mechanism
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of action has yet to be determined, it appears to
prevent ADP-induced exposure of the fibrinogen binding 
site on the platelet glycoprotein Ilb-IIIa complex 
(McTavish et al, 1990) . It is only active after 
repeated oral administration and is rapidly metabolised 
with one metabolite more active than the parent drug. 
In animals, ticlopidine does not reduce thromboxane 
production and therefore, unlike aspirin, does not 
appear to inhibit cyclo-oxygenase (Valentin et al,
1988) .
Studies to determine cytotoxicity of antiplatelet 
agents:
Prior to proceeding to study the effects of aspirin and 
ticlopidine on pulmonary tumour seeding in our animal 
experimental model, it was essential to establish 
whether either agent had a cytostatic or cytotoxic 
effect on the Mtln3 tumour cell line. Two in vitro 
assays, the clonogenic assay and the MTT assay, were 
performed as previously described in Chapter 3. The 
estimated plasma concentrations in the animal
experiment were 3 mgs/ml for aspirin and 15 mgs/ml for 
ticlopidine (see methods, Chapter 3).
For the clonogenic assay, drug was added to flasks (4 
flasks per dose) giving the following range of
concentrations:
Aspirin - 0, 1, 10, 50 and 100 mgs/ml of medium 
Ticlopidine - 0, 10, 50, 100 and 200 mgs/ml of medium
107
For the MTT assay, drug was added to each well (8 wells 
per concentration) giving the following range of
concentrations:
Aspirin - 0, 1, 5, 10, 20, 40, 60, 80 mgs/ml of medium
Ticlopidine - 0, 10, 20, 40, 80, 160, 320 mgs/ml of
medium
RESULTS
Clonogenic assay
The mean number of colonies in the experimental groups 
exposed to aspirin ranged from 195-207 (controls 196) 
and for ticlopidine ranged from 192-204 (controls 197) 
(Table 5) . There was no reduction in the clonogenic
potential of Mtln3 cells exposed to either aspirin or 
ticlopidine.
MTT assay
Spectral absorbance at 570 nm ranged from 2.78-2.83 for 
aspirin (control 2.80) and from 2.73-2.77 for 
ticlopidine (control 2.73) (Table 6). MTT-formazan 
formation was not reduced by exposure to either aspirin 
or ticlopidine.
Therefore aspirin and ticlopidine were not cytotoxic or 
cytostatic for the Mtln3 cell line.
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Effect of Aspirin and Ticlopidine 
onTumour Cells
Table 5 
Clonogenic Assay
Aspirin
(mg/ml)
0 1 10 50 100
Num ber of 
Colonies
196 197 205 195 2 07
Ticlopidine
(mg/ml)
0 10 50 100 200
Num ber of 
Colonies
197
(c)
192 198 204 192
C : Control
Table 6 
MTT Assay
Aspirin
(mg/ml)
0 1 5 10 20 40 60 80
Absorbance
(570nm )
2.80
(c)
2.78 2 .78 2.79 2 .79 2 .83 2 .80 2.81
Ticlopidine
(mg/ml)
0 10 20 40 80 160 320
Absorbance
(570nm )
2.73
(c)
2 .77 2.74 2.74 2 .75 2 .73 2 .7 7
C : Control
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EXPERIMENT 1: Studies to determine the effect of
Streptokinase and aspirin on pulmonary tumour seeding.
MATERIALS AND METHODS
Four groups of female 344 Fischer rats, 8 per group, 6- 
8 weeks old were used in this experiment. Under general 
anaesthesia, animals were given tail vein injections of 
a 0.5 ml suspension of 105 Mtln3 cells in F10/DMEM. 
Additional treatment was then commenced as follows:
Group A: These animals received no additional
treatment.
Group B: These animals received a single intravenous
injection of Streptokinase, in a dose of 30 000 U/kg, 
30 minutes after tumour cell inoculation.
Group C: These animals received a single intravenous
injection of aspirin, in a dose of 20 mgs/kg, 15 
minutes before tumour cell inoculation.
Group D: These animals received an intravenous
injection of aspirin (20 mgs/kg) 15 minutes before 
tumour cell inoculation and a further injection of 
Streptokinase (30 000 U/kg) 30 minutes after tumour
cell inoculation.
The dose of aspirin administered was 20 mgs/kg body 
weight. This was based on previous animal experimental
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work which demonstrated inhibition of ex-vivo platelet 
aggregation (Morikawa et al, 1986) . Aspirin (aspisol, 
Bayer, Leverkusen, FRG) was reconstituted in sterile 
water and administered intravenously to ensure accuracy 
of dosage.
The estimated peak plasma concentration for aspirin in 
a dose of 20 mgs/ml, was 3mgs/ml (see materials and 
methods).
Animals were sacrificed at 17 days and pulmonary tumour 
seeding assessed by the method of Wexler as previously 
described (Chapter 1).
One animal (Group D) did not survive to the end of the 
experimental period. Post-mortem examination did not 
reveal any evidence of haemorrhagic complications and 
the cause of death was unknown.
Comparison of the different groups was made by the 
Mann-Whitney test using Bonferoni1s correction for 
multiple comparisons.
RESULTS (Figure 11)
Animals that received Streptokinase (Group B) showed a 
significant reduction in pulmonary tumour seeding 
(median = 60) when compared with controls (Group A)
that received tumour cells alone (median = 114, p <
0.01). There was a reduction in pulmonary tumour 
seeding in animals that received aspirin (Group C, 
median = 87.5) although this failed to reach
statistical significance when compared with controls (p
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= 0.052) . Those animals that received both aspirin and 
Streptokinase (Group D) also showed a significant 
reduction in pulmonary tumour seeding (median = 60.5) 
in comparison with controls, although this effect was 
not significantly different from the reduction in 
pulmonary tumour seeding demonstrated in the group 
treated with Streptokinase alone.
EXPERIMENT 2: Studies to determine the effects of
ticlopidine on pulmonary tumour seeding.
MATERIALS AND METHODS
Four groups of female 344 Fischer rats, 10 per group, 
6-8 weeks old were used in this experiment. Under 
general anaesthesia, animals were given tail vein 
injections of a 0.5 ml suspension of 105 Mtln3 cells in 
F10/DMEM. Additional treatment was then commenced as 
follows:
Group A: These animals received no additional
treatment.
Group B: These animals received a single intravenous
injection of Streptokinase in a dose of 30 000 U/kg 30 
minutes after tumour cell inoculation.
Group C: These animals received oral ticlopidine in a
dose of 100 mgs/kg for 3 days prior to tumour cell 
inoculation.
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Group D: These animals received oral ticlopidine in a 
dose of 100 mgs/kg for 3 days prior to tumour cell 
inoculation and intravenous Streptokinase in a dose of 
30 000 U/kg 30 minutes after tumour cell inoculation.
The estimated peak plasma concentration for ticlopidine 
in a dose of lOOmgs/ml, was 15 mgs/ml (see materials 
and methods).
Animals were sacrificed and pulmonary tumour seeding 
assessed by the method of Wexler.
Two animals (one in Group C, one in Group D) did not 
survive to the end of the experimental period. Post­
mortem examination did not reveal any evidence of 
haemorrhagic complications and the cause of death was 
unknown.
Statistical analysis was made by Mann-Whitney test 
using Bonferoni's correction for multiple comparisons.
RESULTS (Figure 12)
Animals that received Streptokinase (Group B) showed a 
significant reduction in pulmonary tumour seeding 
(median = 73) when compared with control animals (Group 
A) that received tumour cells alone (median = 132, p < 
0.005). Animals that received ticlopidine (Group C) 
also demonstrated a significant reduction in pulmonary 
tumour nodules (median = 92) in comparison with
controls (p < 0.005) . The reduction in pulmonary tumour 
seeding in animals that received Streptokinase was
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Figure 12
Effect of Streptokinase and Ticlopidine 
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significantly greater than in those animals that 
received ticlopidine alone (Group B vs C, p < 0.01). 
However, the reduction in pulmonary tumour seeding in 
those animals that received both ticlopidine and 
Streptokinase (Group D) was not significantly different 
to those that received Streptokinase alone.
DISCUSSION
The mean number of pulmonary tumour deposits per group 
in the two experiments above were higher than the mean 
number of pulmonary tumour deposits per group in the 
rt-PA/Streptokinase experiment. This is due to
phenotypic drift (Neri and Nicolson, 1981) and is the 
result of using tumour cell suspensions derived from 
tumour colonies of different passage number for 
different experiments. While this prevents comparison 
between experiments it does not affect comparison 
between groups within the same experiment.
Platelets, like fibrin, are an integral 
component of tumour thrombi which become trapped in the 
microcirculation of target organs. In addition, they 
are thought to play a major role in reducing the 
efficiency of thrombolytic therapy by inducing platelet 
activation (Fitzgerald et al, 1988, 1989; Vaughan et
al, 1991). Consequently, antiplatelet therapy has been 
advocated during coronary thrombolysis to enhance 
vessel patency and the combination of Streptokinase and
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aspirin has been shown to be superior to the use of 
either agent alone (ISIS-2, 1988). It was therefore 
hypothesized that combined antiplatelet/fibrinolytic 
therapy would have a greater inhibitory effect on 
pulmonary tumour seeding than either treatment alone.
Our results demonstrate that aspirin in a dose 
of 2 0 mgs/kg reduced pulmonary tumour seeding although 
this effect failed to reach a significant level when 
compared with untreated controls. Furthermore, the 
combination of aspirin and Streptokinase was no more 
effective in preventing pulmonary tumour seeding than 
Streptokinase treatment alone. The negative results 
with aspirin reported in other animal models (Wood and 
Hilgard, 1972; Hilgard et al, 1976) have been ascribed 
to the use of high doses of aspirin. Recognition of the 
inhibitory effect of aspirin on endothelial cell 
prostacyclin (PGI2) production (Kelton et al, 1978) has 
led to the use of low dose aspirin which preferentially 
inhibits production of the potent platelet aggregator 
thromboxane A2 by causing irreversible acetylation of 
the enzyme cyclo-oxygenase. Since tumour cell-induced 
platelet activation may occur via other pathways such 
as the generation of thrombin, activation by ADP or a 
combination of these mechanisms (Bastida et al, 1984; 
Honn et al, 1987), failure to demonstrate a significant 
antimetastatic effect in this study suggests that 
platelet activation by the Mtln3 cell line may be 
independent of the cyclo-oxygenase pathway. In
contrast, ticlopidine significantly inhibited the
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development of pulmonary tumour nodules suggesting that 
tumour cell-induced platelet aggregation by the Mtln3 
cell line may be dependent on the generation of ADP. 
However, like aspirin, the combination of ticlopidine 
and Streptokinase was no more effective in tumour 
inhibition than Streptokinase treatment alone. These 
results indicate that fibrinolytic inhibition of 
metastasis is not enhanced by antiplatelet therapy and 
suggest that tumour cell-platelet interactions may be 
less important than fibrin deposition in the metastatic 
process.
The preceding four chapters have shown that a 
single "clot-lysis" dose of Streptokinase or rt-PA can 
inhibit pulmonary metastasis in an animal model. This 
effect is likely to be due to destruction of fibrin 
clot surrounding tumour thrombi trapped in the 
pulmonary microcirculation. If these results are 
applicable to the human metastatic process then 
fibrinolytic agents may have a role in the treatment of 
patients with malignant disease. Previous clinical 
studies of anticoagulant therapy have been compromised 
by a preponderence of patients with advanced disease 
and established metastasis. However, the study of White 
et al (1976), using urokinase to facilitate 
fibrinolysis in human malignancy, has shown that 
patient survival may be improved by prevention of 
entrapment of circulating malignant cells in the 
microvasculature. It is clear that to be effective, 
antimetastatic therapy should be administered to
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patients at risk from haematogenous dissemination in 
order to prevent seeding of circulating tumour cells in 
secondary organs. Therefore the development of an 
antimetastatic treatment in an animal model is only 
relevant if this therapy can have clinical application 
in patients with cancer.
Evidence from animal studies has demonstrated 
that the manipulation of malignant tumours is 
associated with increased tumour cell shedding into the 
bloodstream (Cliffton and Agostino, 1960; Romsdahl et 
al, 1964; Liotta et al, 1974) and may lead to an 
increase in the development of distant metastases 
(Tyzzer, 1913; Liotta et al, 1976). These findings 
suggest that operative manipulation may also enhance 
the human metastatic process implying that fibrinolytic 
therapy applied peri-operatively might inhibit this 
type of metastatic seeding. Although many studies have 
attempted to identify circulating tumour cells in 
cancer patients, the results have been unreliable due 
to the problems associated with the detection of a 
minor sub-population of tumour cells in blood. In view 
of the potential risk of peri-operative haemorrhage 
with fibrinolytic agents it would be difficult to 
justify a large prospective study of peri-operative 
fibrinolytic therapy without conclusive evidence of 
tumour cell shedding during surgery.
The experimental work in the second half of this 
thesis is designed to establish whether tumour cell 
dissemination occurs during surgery for malignant
119
disease. This will determine whether there is a future 
role for the prescription of peri-operative 
antimetastatic therapy in these patients.
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CHAPTER 5
FLOW CYTOMETRIC DETECTION OF TUMOUR CELLS IN BLOOD 
INTRODUCTION
The metastatic process is a complex, cascade process 
which is initiated by intravasation of malignant cells 
from the primary tumour into the circulation. The 
intensity of vascularisation and the presence of 
vascular invasion in the primary tumour correlates with 
the development of metastatic disease (Willis, 1930; 
Weidner et al, 1991) . The identification and 
enumeration of circulating tumour cells within the 
bloodstream may therefore be used to predict patients 
at risk from secondary spread.
At the present time, the role of surgery in 
human cancer dissemination is unclear due to the 
unreliability of techniques for cancer cell isolation 
and identification (Goldblat and Nadel, 1965). This 
has been attributed to difficulties in the 
interpretation of cellular morphology. As a result 
large primitive blood cells normally present in blood, 
including precursors of the erythroid, myeloid and 
lymphoid series, have frequently been misinterpreted as 
malignant leading to an overestimation of tumour cell 
numbers (Landell et al, 1963; Goldblatt and Nadel, 
1965) .
As reliable estimates of circulating cells 
are required to assess the role of surgery in the
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metastatic process, new techniques have been adopted in 
an attempt to avoid the difficulties encountered in 
previous studies. The development of immunocytological 
techniques has greatly enhanced the specificity and 
sensitivity by which tumour cells can be detected in 
bone marrow (Osborne et al, 1991) and blood (Moss and 
Sanders, 1990) . The use of a monoclonal antibody to a 
tumour-specific antigen should therefore enable the 
accurate detection of a minor subpopulation of tumour 
cells in blood. Standard immunocytochemical analysis of 
blood would necessitate laborious and possibly 
inaccurate microscopy studies, however the relatively 
new technique of flow cytometry has the capability to 
screen individual cells for their light scattering 
abilities (which provides information on their size and 
granularity) as well as their fluorescent intensity 
when labelled with fluorochrome conjugated monoclonal 
antibody. The emissions from fluorochrome-labelled 
cells are automatically detected and quantified and 
converted to digital data thereby simplifying the 
process of immunocytochemical analysis of blood. The 
aim of this series of experiments was therefore to 
investigate whether flow cytometry was a suitable 
technique to screen large numbers of peripheral blood 
cells to identify circulating tumour cells prior to 
its application in patients with malignant disease.
To identify circulating tumour cells in the 
peripheral blood of patients with breast cancer 
requires the use of specific monoclonal antibodies that
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can distinguish between haemopoetic cells and malignant 
breast epithelial cells. Transformation to the 
malignant phenotype is associated with heterogeneity of 
antigen expression and monoclonal antibodies to 
epithelial tissues may bind to only some cells in a 
tumour (Edwards, 1985). Preliminary flow cytometry 
experiments were therefore designed to compare the 
binding affinity of five monoclonal antibodies (MNF116, 
Anti-EMA, HMFG1, SM3, Ber-EP4) that react with 
different breast epithelial antigens in order to 
establish which antibody produced optimal fluorescent 
labelling of tumour cells in peripheral blood. Having 
established the specificity and sensitivity of the 
technique, a pilot study of patients with breast cancer 
was designed to establish whether flow cytometry could 
identify circulating tumour cells in the bloodstream in 
the perioperative period. To maximise tumour cell 
detection and avoid tumour cell loss from filtration 
in the pulmonary microcirculation, central venous 
access was achieved and blood samples were obtained.
1 PRELIMINARY EXPERIMENTS
MATERIALS AND METHODS
Monoclonal Antibodies Reacting With Breast Epithelia
The technique of monoclonal antibody (MAB) production 
has changed little since the original work of Kohler
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and Milstein (1975) and is based on the principle of 
fusing stimulated B cells (usually from the spleen of a 
mouse or rat) with drug-selected non-immunoglobulin- 
secreting murine myeloma cells. The use of monoclonal 
antibodies specific to breast antigens enables breast 
epithelial cells circulating in the bloodstream to be 
distinguished from haemopoetic cells. Although some of 
these antibodies show preferential reaction with breast 
cancer tissue, they do not detect cancer specific- 
antigens; rather, they react with normal or modified 
tissue antigens which are either preferentially or 
inappropriately expressed on malignant cells (Tjandra 
and McKenzie, 1988) .
1 Anticytokeratins
The antigenic determinants for this class of antibody 
are the cytokeratin proteins which form the 
intermediate filaments in the cytoplasm of all 
epithelial cells. A total of 19 proteins, related to 
but not identical with epidermal alpha keratins, have 
been identified with molecular weights varying from 
40,000 to 68,000 kilodaltons (Moll et al, 1982). The 
pattern of cytokeratin expression is different for each 
epithelium and for normal breast epithelium this 
includes a broad range of cytokeratins from low to high 
molecular weight. Although this pattern is altered by 
malignant transformation Cytokeratins 8, 18 and 19 are
consistently expressed by breast carcinoma cells 
(Jarasch et al, 1988; Tsuburu et al, 1991). Endothelial
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cells, stromal cells and cells of haemopoietic origin 
do not express cytokeratin filaments (Lazarides, 1980).
The anticytokeratin monoclonal antibody 
utilized, MNF 116 (Dako Ltd., High Wycombe, Bucks, 
England), was originally derived from a crude extract 
of splenic cells from a nude mouse engrafted with the 
breast carcinoma cell line MCF7. The antibody reacts 
with an epitope which is present on a wide range of 
Cytokeratins, varying in molecular weight from 45 -
56.5 kilodaltons, including 10, 17 and 18. This IgGl
antibody was obtained conjugated to fluorescein 
isothiocyanate (FITC) giving a FITC/protein ratio 
(E495nm/E278nm) of approximately 1.0.
2 Anti-Polymorphic Epithelial Mucins
Milk mucins, now termed Polymorphic Epithelial Mucins 
(PEM), are large, cell surface-associated glycoproteins 
(50-60% carbohydrate) that are characteristic, but not 
speciifc to, breast epithelial cells. The sugar side 
chains are linked to the serines and threonines through 
the sugar N-acetyl galactosamine. Many of these 
antibodies were raised by immunization of mice with 
extracts of the human milk fat globule membranes (HMFG) 
which are surface membranes that surround milk 
triacylglycerol droplets secreted from mammary 
epithelial cells. One of the first and most widely used 
monoclonal antibody in this class is HMFG1 originally 
produced by immunizing mice with the HMFG membrane and 
cultured human milk cells (Taylor-Papadimitriou et al,
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1981) . Over the years these antigens have become known 
by the monoclonal antibody-defined epitopes and include 
B72.3. DF3, NCRC 11 and SM3. The amino acid sequence 
coding for the core protein of the milk mucin (PEM) has 
been determined by cDNA cloning (Gendler et al, 1990) 
and it has been established that the various antibodies 
recognise an epitope found within a tandem repeat 
element comprising 2 0 amino acids in the core protein 
(Siddiqui et al, 1988) . Over 90% of breast cancers 
react with these antibodies (Berry et al, 1985; Thomas 
et al, 1987) .
The antibodies utilized in this experiment were 
HMFG1, SM3 and anti-EMA. HMFG1 and SM3 were kindly 
donated by Dr. J Taylor-Papadimitriou (Institute of 
Cancer Research, London) in an unconjugated form. Anti- 
EMA was obtained conjugated to FITC giving a 
FITC/protein ratio of 1.1 (Dako Ltd., U.K.).
3 Ber-EP4
This relatively new murine monoclonal antibody was 
produced by standard hybridoma techniques using the MCF 
7 breast carcinoma cell line. It is directed against 
two membrane glycoprotein antigens (34 and 49kD mol. 
wt. ) which are distinct from other surface antigens, 
including EMA and related antigens (Latza et at, 1990). 
All carcinomas and non-neoplastic epithelial cells 
express the Ber-EP4 antigen except the superficial 
layers of squamous epithelia, hepatocytes and parietal 
cells.
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The antibody was obtained conjugated to FITC 
giving a FITC/protein ratio of 1.1 (Dako Ltd., High 
Wycombe, U.K.).
Tumour Cells
Three cultured breast carcinoma cell lines, ZR75, MCF7 
and MDA/MB/231, were utilized for monoclonal antibody 
labelling studies and were obtained from the Department 
of Oncology, Beatson Institute, University of Glasgow. 
The original clones were isolated from malignant 
pleural effusions in patients with metastatic breast 
carcinoma as this source provides a large number of 
tumour cells with high viability and minimal fibroblast 
contamination (Soule et al, 1973; Cailleau et al, 1974; 
Engel et al, 1978) .
Cells were cultured in 75 cm2 tissue culture 
flasks (Gibco, Paisley) in RPMI medium, with 10% foetal 
calf serum (FCS) but without antibiotics. Cultures were 
maintained at 37° C in equilibrium with 2% C02 in air. 
Once cultures were confluent, passage was carried out 
by washing with 5 ml of trypsin/EDTA (0.25%/lmM) and 
incubated for 5 minutes at 37 degrees C. Subcultures 
required the addition of 2 x 106 viable tumour cells to 
further 75 cm2 flasks.
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Flow Cytometry
FACScan Analyser
Quantitative analysis of tumour cells in blood was 
performed by flow cytometry using a FACScan analyser 
(Becton Dickinson, Oxford, U.K.). This cytometer
analyses cell suspensions by utilizing a low energy 15
mW Argon ion gas laser and measures and records up to 
five parameters on an individual cell. The forward 
scatter of the laser light (FSC) is related to cell 
size, like the shadow of a cell, while the 90 degree 
side scatter (SSC) is the light reflected from the cell 
and is related to granularity. In addition, the binding 
of up to three fluorochromes conjugated to monoclonal 
antibodies can be measured.
The energy level of the Argon ion laser is 
sufficient to stimulate and cause maximal energy
emission from the f luorochromes and the fixed 
wavelength of 488 nm only excites fluorochromes in the 
red/green spectrum. The fluorochromes used in this 
study were fluorescein isothiocyanate (FITC) which 
emits in the green waveband from 480nm to 600nm and 
phycoerythrin (PE) which emits in the orange-red
waveband from 550nm to 640nm.
FACScan Analysis
Sample analysis requires prepared cell suspensions to 
be placed in cytometer tubes (Falcon 2 052) which are 
then pushed over the sample pipette of the FACScan and
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held in place by a rubber grommet to give an airtight 
seal. Air is then pumped into the tube increasing the 
pressure and propelling the sample into a conical 
chamber in the flow cell. Laminar flow is produced by a 
stream of isotonic sheath fluid driven under pressure, 
causing the cells to form a single stream as they leave 
the conical chamber and enter the flow cell, at a rate 
of 60ul/min, where they are exposed to the Argon ion 
laser.
The laser beam is first passed through a 
prismatic refracting beam expander and converging lens 
before being focused on the stream of cells by a 
steering plate. The forward scatter is recorded on a 
silicon photodiode lying in the path of the laser while 
the side scatter is reflected and collected together 
with the fluorochrome emissions, and converted into 
parallel light by a bi-convex lens. The side scatter, 
green (FL1), orange-red (FL2) and strong red (FL3) 
fluorescence are separated according to wavelength by a 
series of mirrors and filters. Separate photoelectric 
multipliers detect and amplify the side scatter and 
fluorochrome emissions which are then converted to 
digital data by an analog/digital converter. The data 
is collected and stored on the software programme 
FACScan Research and displayed on a four decade log 
scale.
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Conjugation of Monoclonal Antibodies with Fluorescein 
Isothiocyanate
The immunoglobulins (HMFG1, SM3) were first dialysed 
for 24hrs in a carbonate buffer (0.25 M sodium 
carbonate pH 9.0 containing 0.1 M sodium chloride) to 
give a protein concentration of 10-20 mg/ml. 0.05mg of 
fluorochrome isothiocyanate (FITC) per mg of protein 
was added and mixed at 4° C for 12hrs. The mixture was 
then applied to a Sephadez G25 column (3 x 15cm) and 
eluted with PBS. Two coloured fractions were visible in 
the column and the first one was collected (conjugate) 
while the second was discarded (unbound fluorochrome).
The fluorescein/protein ratio was calculated by 
measuring the absorbance of the conjugate at 280 and 
4 95nm:
2.87 x A495 
Molar ratio = A280 - 0.35 x A495
The fluorescein/protein ratio for HMFG1 and SM3 was 
calculated at 0.55.
Sample Preparation
Tumour cells were prepared from subconfluent cultures 
by trypsinization with trypsin/EDTA (0.25%/lmM), washed 
(x2) in phosphate buffered saline (PBS) by 
centrifugation at 200g for 5 minutes and finally 
resuspended in PBS. To enable intracellular monoclonal 
antibody labelling of cytokeratins by MNF 116, cells 
were permealized by the addition of 70% alcohol,
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incubated on ice for 3 0 minutes and washed (x2) in 
PBS. This stage was not necessary for labelling with 
surface binding monoclonal antibody. Ten ul of the 
appropriate MAB was then added to 106 cells suspended 
in 200ul PBS and incubated on ice, in the dark, for 20
minutes. Cells were washed and resuspended in 0.5 ml
PBS for flow cytometric analysis.
Erythrocyte Lysis
For flow cytometric analysis of whole blood, 
erythrocytes were first removed using an ammonium 
chloride erythrocyte lysing solution. The lysing
solution was mixed with whole blood in a ratio of 4:1
and incubated at room temperature for 10 minutes with 
gentle mixing. A pellet of peripheral blood leucocytes 
was prepared by centrifugation at 2 00g for 5 minutes, 
washed (x2) in phosphate buffered saline (PBS) and 
finally resuspended in PBS.
The osmotic fragility of erythrocytes ensures 
that this technique is specific for erythrocyte lysis. 
A preliminary study using a tumour cell suspension 
confirmed that the lysis solution did not disrupt 
tumour cell membranes.
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EXPERIMENTS 
1 One Colour Flow Cytometric Analysis
1.1 Studies to determine monoclonal antibody binding 
affinity for tumour cells
The homogeneous expression of surface and cytoplasmic 
antigens in benign breast epithelial cells is altered 
in the transformation to the malignant phenotype. 
Malignant breast cells exhibit a broad spectrum of 
antigenic expression and either surface or 
intracellular antigens may be preferentially retained. 
This experiment was designed to establish whether 
fluorochrome-conjugated monoclonal antibodies reacting 
with cytokeratins or cell membrane antigens differed in 
their ability to label a tumour cell population.
Tumour cells were prepared from subconfluent 
cultures and 106 cells from each cell line (ZR 75, MCF 
7, MB/MDA 231) were labelled with lOul of MAB (FITC 
conjugated HMFG1, SM 3, EMA, Ber-EP4, MNF 116) as 
described above. Cell suspensions were analysed by 
FACScan and 10, 000 events were collected in list mode 
for multiparametric analysis using the FACScan software 
programme. The flow cytometer was calibrated for 
maximal tumour cell detection by adjustment of gain and 
amplitude settings using an unlabelled tumour cell 
sample (negative control). The limit of sensitivity of 
the FACScan was 1000 FITC equivalent molecules per cell
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and the resultant range of cellular fluorescence was 
displayed on a four decade log scale.
RESULTS
The results of monoclonal antibody labelling with FITC 
of the three tumour cell lines are shown in Figure 13 
and 14. A logarithmic scale of green fluorescence (FL1) 
is plotted on the horizontal axis and the number of 
events (cells) is plotted on the vertical axis. The red 
graph on each histogram represents a control population 
of unlabelled tumour cells expressing low intensity 
green fluorescence due to endogenous production of 
naturally fluorescent molecules from culture medium 
(autofluorescence). Figure 13a demonstrates that HMFG1 
and SM3 produce an identical fluorescent pattern with 
all three cell lines (green and yellow graph
respectively) suggesting that they identify a closely 
related epitope. Figures 13b, 14a, and 14b represent
the results of MAB labelling of tumour cells with anti- 
EMA, Ber-EP4 and MNF 116 respectively. It can be seen 
that for all three tumour cell lines, the
anticytokeratin antibody, MNF 116, gives the strongest 
intensity of fluorescence.
1.2 Tumour cell/leucocyte separation by one colour flow 
cytometry
This experiment was designed to assess the ability of 
one colour flow cytometry to separate tumour cells and
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leucocytes using a fluorochrome conjugated monoclonal 
antibody specific for cytokeratin 18.
Cultured breast carcinoma cells (ZR75) were 
seeded into a 1 ml suspension of peripheral blood 
leucocytes prepared by lysis of whole blood (see 
methods section, Chapter 5), centrifuged at 200g for 5 
minutes and resuspended in 200 ul of PBS prior to 
labelling with FITC/MNF 116 as previously described. 
Two control samples were prepared; a suspension of 106 
peripheral blood leucocytes served as a negative 
control while a suspension of 106 ZR 75 tumour cells 
served as a positive control. Analysis on FACScan was 
carried out using the gain/amplitude settings of 
experiment 1.
RESULTS
One colour flow cytometric analysis enables separation 
of tumour cells and peripheral blood leucocytes (Figure 
15a). Tumour cells form a distinct population of highly 
fluorescent cells due to the binding of the 
fluorochrome-conjugated anticytokeratin antibody. In 
contrast, peripheral blood leucocytes fail to bind the 
epithelial-specific antibody and exhibit low intensity 
autofluorescence. On closer inspection it can be seen 
that this separation is incomplete and there is an 
overlap between highly autofluorescent leucocytes and 
weakly fluorescent tumour cells (Figure 15b). 49.46% of 
tumour cells express a similar intensity of 
fluorescence to leucocytes. Therefore the exclusion of
Figure 15. 135
One colour separation of leucocyte/tumour cell populations.
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all leucocytes during FACScan analysis of blood for 
tumour cells by one colour flow cytometry would have 
been associated with a 50% loss of tumour cells.
2 Two Colour Flow Cytometric Analysis
2.1 Tumour cell/leucocyte separation by two colour flow 
cytometry
An attempt was made to enhance the separation of tumour 
cells and peripheral blood leucocytes using two colour 
analysis. This required dual labelling of blood samples 
with tumour and leucocyte specific monoclonal 
antibodies conjugated to different fluorochromes. 
Tumour cells labelled with FITC expressed green 
fluorescence (FL 1) while leucocytes labelled with 
phycoerythrin (PE) expressed red fluorescence (FL 2).
Antibodies that react with peripheral blood leucocytes
Anti-LFA-1
This murine monoclonal antibody was produced by 
standard hybridoma techniques and recognises a cell 
surface a/b heterodimeric glycoprotein of 180kDa 
molecular weight within the CDlla cluster. The CDlla 
antigen is a member of the integrin supergene family of 
adhesion molecules and binds to ICAM-1, mediates cell­
cell adhesion and may participate in lymphocyte 
activation. All leucocytes, myeloma and neuroectodermal
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cells show strong reactivity. 100% activated T cells, 
9 9% peripheral lymphocytes, 97% peripheral monocytes 
and 97% peripheral granulocytes react positively. This 
antibody was obtained conjugated to the red
fluorochrome Phycoerythrin (PE) (Serotec, Oxford, 
U.K.).
106 ZR75 cells were diluted in PBS and added to 106 
peripheral blood leucocytes. In addition two control 
samples were prepared; a suspension of 106 peripheral
blood leucocytes served as a negative control while a 
suspension of 106 ZR75 tumour cells served as a
positive control. The specimens were resuspended in 100 
ul of PBS and permealized with 70% ethanol as 
previously described. Ten ul of MNF 116 and anti-LFA 
were added and samples were then incubated for 2 0 
minutes in the dark on ice. After washing with PBS, 
specimens were resuspended in 0.5 ml for FACScan 
analysis.
RESULTS
Figure 16a shows the separation of tumour cell and 
leucocyte populations achieved by two colour FACScan 
analysis. The majority of PE-labelled leucocytes
exhibit high red fluorescence and can easily be 
distinguished from tumour cells with low red 
fluorescence. On closer inspection it can be seen that 
this separation is incomplete and a small proportion of 
PE-labelled leucocytes (8.26%) express a similar level
Figure 16.
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of red fluorescence to tumour cells (figure 16b) . The 
exclusion of those leucocytes with high red 
fluorescence (FL2 channel) prior to analysis for green 
fluorescence (FLl channel, figure 16c), enabled the 
complete exclusion of leucocytes with green 
fluorescence in combination with a 22.62% exclusion of 
tumour cells.
In summary, two colour flow cytometric analysis 
of blood for tumour cells reduced tumour cell loss to 
less than 25% after exclusion of all leucocytes.
2.2 Sensitivity Assay
The viability of circulating tumour cells is short 
lived and many may be lost or destroyed during the 
processing of blood for FACScan analysis. A sensitivity 
assay was therefore performed to guage the overall 
efficiency of tumour cell recovery from blood.
ZR75 cells were serially diluted in PBS and 
added to 1 ml samples of blood. Suspensions of ZR 75 
cells at 10, 100, 1000, 10000, and 100000/ml blood were 
made. Erythrocytes were lysed and samples labelled with 
MNF 116 and anti-LFA as previously described. Each 
dilution was repeated 5 times. Gating criteria for 
FACScan analysis were established using an unseeded 
leucocyte sample as a negative control.
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RESULTS
Table 7 shows that the number of cells with high 
FLl/low FL2 fluorescence increased with an increasing 
concentration of ZR 75 cells in blood. It can be seen 
that the efficiency of tumour cell recovery varies 
according to the number of tumour cells initially 
seeded in blood. At low tumour cell concentrations (< 
103 cells/ml) recovery was inefficient and less than 
50% of seeded tumour cells were detected. At high 
concentrations the efficiency of recovery was greater 
such that 105 cells could be recovered with an 
efficiency of 67.3%.
PATIENT STUDY
MATERIALS AND METHODS
Blood Sampling Procedure
Approval for this study was granted by the Western 
Infirmary Ethical Committee. Fourteen patients with 
breast cancer and four patients with benign breast 
disease had a central venous catheter inserted under 
local anaesthetic, into the antecubital vein in the 
anticubital fossa on the ipsilateral side of the breast 
lesion. Under radiological guidance the catheter was 
advanced into the subclavian vein and the position of 
the tip ascertained by the injection of radiopaque 
dye. During sampling a venous tourniquet was placed on
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Table 7
Efficiency of Tumour Cell Recovery from 
Blood by Two Colour Flow 
Cytometric Analysis
No. of Z R  75  
cells/m l blood
Sam ple m ean no. 
of Z R  75  cells
Efficiency of 
recovery (% )
10 0.2 2 .0
50 5 .6 11 .2
102 19.9 19 .9
103 4 5 6 .7 4 5 .7
104 6 4 5 4 .2 6 4 .6
105 6 7 3 2 0 .8 67 .3
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the ipsilateral upper arm to reduce the dilutional 
effect of blood returning from the upper limb.
A 5 ml pre-operative sample was taken 
immediately after insertion of the catheter. A further 
5 ml intra-operative sample was taken at the point of 
maximal tumour manipulation. For "lumpectomy" this 
coincided with grasping of the tumour by forceps prior 
to excision, and for mastectomy coincided with lateral 
stripping of the breast from the chest wall. A post­
operative 5 ml sample was taken 24 hours after 
completion of the surgical procedure. All samples were 
immediately placed in EDTA anticoagulated tubes.
Sample Analysis
All samples were immediately treated with erythrocyte 
lysing solution and resuspended in PBS for dual 
antibody labelling with FITC-conjugated MNF 116 and PE- 
conjugated anti-LCA as previously described. Gating 
criteria for FACScan analysis were established using an 
unseeded leucocyte sample, prepared from a healthy 
female volunteer, as a negative control. The maximum 
green (FITC) fluorescence on this sample was then used 
to set the lower limit of the green gate to screen the 
patient samples for tumour cells.
RESULTS
No cells expressing high fluorescence were detected by 
FACscan analysis in any of the peri-operative blood
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samples from patients undergoing surgery for either 
benign or malignant breast disease.
DISCUSSION
The purpose of the preliminary experiments was to 
determine the specificity and sensitivity of flow 
cytometry to detect breast cancer cells in blood prior 
to applying it to a prospective clinical study in 
patients to determine whether the presence of these 
cells in the bloodstream peri-operatively is a 
predictor of poor prognosis. In contrast to 
immunocytochemical techniques where the malignant 
nature of an antibody-labelled cell can be confirmed 
morphologically, the diagnosis of malignancy by flow 
cytometry is solely determined by the single parameter 
of fluorescence. Since the number of peripheral blood 
leucocytes per ml of blood is approximately 107, the 
inclusion of only 1% of peripheral blood leucocytes 
would lead to a significant overestimation of tumour 
cell numbers (approximately 105 false positive 
events/ml of blood). In these experiments it was 
therefore essential that the fluorescent threshold for 
tumour cell detection was sufficiently high to exclude 
all peripheral blood leucocytes.
The results of the first experiment demonstrated 
that a monoclonal antibody directed against the 
epithelial cytoskeleton produced optimal labelling of 
cultured breast carcinoma cells. The specificity of 
this antibody is well characterised and it reacts with
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the majority of primary breast cancers but not with 
normal blood elements (Lazarides, 1980).
One colour flow cytometric analysis of a mixed 
leucocyte/tumour cell population using the 
anticytokeratin antibody showed incomplete separation 
of antibody-labelled tumour cells and peripheral blood 
leucocytes. Consequently, the exclusion of all 
leucocytes during blood analysis would have resulted in 
the loss of half of the total number of tumour cells. 
Two colour analysis enhanced tumour cell detection by 
enabling the exclusion of all peripheral blood 
leucocytes with less than a 25% loss in tumour cells. 
An assessment of sensitivity showed that the efficiency 
of tumour cell recovery varied according to the number 
of cells initially seeded into normal blood. The 
greater efficiency in tumour cell recovery at high cell 
concentrations emphasizes that the proportionately 
fewer cells detected after monoclonal antibody 
labelling of low cancer cell concentrations was due to 
mechanical and dispersion factors rather than inherent 
differences in cell fluorescence.
A pilot clinical study of two colour flow 
cytometry did not demonstrate any circulating breast 
epithelial cells in patients with benign or malignant 
breast disease in the peri-operative period. These 
results are in contrast to the preliminary findings of 
Nusbaum (1991) who used flow cytometry to identify 
anticytokeratin-labelled urothelial cells in the blood 
of patients undergoing urological surgery. This study
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demonstrated the presence of circulating tumour cells 
in the peripheral blood of 7 of 11 patients (64%) 
although positive events were rare and analysis for 
more than an hour was frequently required to detect 1 
cytokeratin positive cell per 106 leucocytes. However, 
gating criteria using a negative control were inferior 
to our study (one colour analysis of 104 leucocytes vs 
two colour analysis of 106 leucocytes) and thus such a 
low incidence of positive events after prolonged 
analysis could represent ungated leucocytes. 
Furthermore, it should be stressed that while 
preliminary studies demonstrated strong staining of 
cell lines with anticytokeratin antibody, the intensity 
of primary tumour staining was more variable. It is 
therefore possible that gating criteria may have 
excluded a significant proportion of primary tumour 
cells with low fluorescence.
While the results of our study may indicate an 
absence of tumour cell shedding during operative 
manipulation, a failure of the sampling technique 
cannot be discounted. Central venous catheterisation 
enabled samples to be obtained before the majority of 
tumour cells were removed by filtration in the 
pulmonary microcirculation (Fidler, 1970; Glaves, 
1980). Direct cannulation of tumour draining veins was 
unsuccessful, either because the axillary or internal 
mammary veins were not identified or were too small to 
enter, and the catheter was thus left in a high flow, 
wide diameter vein. Animal studies have demonstrated
147
that cell shedding during manipulation is rapid and 
short-lived (Cliffton and Agostino, 1961; Romsdahl et 
al, 1965; Gazet, 1966). Since sampling was performed 
at a fixed point in time it is possible that if the 
catheter was not in close proximity to tumour draining 
veins and sampling did not coincide with maximal tumour 
manipulation, then tumour emboli could potentially 
escape detection due to rapid haemodilution and 
flushing into the systemic circulation. Axial flow, 
which keeps the cellular components of blood close to 
the vessel wall while maintaining the catheter within 
the central lumen, could have enhanced this loss. 
Continuous or intermittent operative venous sampling 
might have provided a more fail-safe mechanism to 
ensure tumour cell detection, but the processing of 
such a large volume of blood would have not have been 
practical both from the the point of view of the 
quantity of antibody required and the duration of 
analysis by FACScan.
In summary, flow cytometry has failed to 
demonstrate peri-operative tumour cell shedding in 
patients with breast cancer. It has not however, 
provided conclusive evidence that surgical manipulation 
does not enhance cell shedding, in view of its 
unreliability in detecting tumour cells at low 
concentrations as well as the problems encountered with 
venous sampling. It is clear that a more sensitive 
technique of tumour cell detection is required in order
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to establish the significance of peri-operative tumour 
manipulation on the metastatic process.
149
CHAPTER 6
REVERSE TRANSCRIPTASE AND POLYMERASE CHAIN REACTION TO 
DETECT BREAST CARCINOMA CELLS IN PERIPHERAL BLOOD
INTRODUCTION
The preceding chapter has shown that immunofluorescent 
analysis of blood by flow cytometry is not a sensitive 
method to detect circulating tumour cells in patients 
with breast cancer. It is clear that a more sensitive 
and specific technique is required to detect tumour 
cells in blood in order to investigate the hypothesis 
that intra-operative manipulation of malignant 
neoplasms facilitates tumour cell dissemination into 
the bloodstream.
The Polymerase Chain Reaction (PCR) is a newly 
developed molecular biology technique that has the 
ability to amplify a particular sequence of either DNA 
or RNA and can potentially detect one cell in 106 
normal cells (Mullis et al, 1986; Saiki et al, 1985; 
Schochetman et al, 1989). It therefore has the 
necessary sensitivity to detect small numbers of tumour 
cells in peripheral blood by amplification of specific 
DNA sequences. No tumour-specific genes have been 
identified for breast cancer but since epithelial cells 
are not normally present in peripheral blood, genes 
specific to epithelial tissue might be suitable targets 
for the detection of circulating malignant breast 
epithelium. To target epithelial-specific gene
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transcription requires a technique whereby 
complementary DNA (cDNA) can be prepared by reverse 
transcription of blood messenger RNA (mRNA). This 
ensures that only genes that are being actively 
expressed are represented in the cDNA. The aim of the 
following series of experiments was to assess the 
ability of reverse transcriptase and the polymerase 
chain reaction to detect circulating malignant breast 
epithelium.
The level of gene expression varies according to 
the prevalence of the encoded protein. It was therefore 
decided to compare two genes encoding structural 
epithelial proteins for which the genomic organisation 
and cDNA sequence were known. Cytokeratin 18 (CK 18) is 
one of the human cytokeratin polypeptides which 
constitutes the intermediate filaments within the 
cytoplasm of all epithelial cells (see previous 
chapter). CK 18 is expressed by the majority of breast 
carcinomas (Jarasch et al, 1988; Tsubura et al, 1991) 
and while it is also found in diverse simple 
epithelium, trachea and transitional epithelium, it is 
not expressed by haemopoetic and vascular endothelial 
cells (Moll et al, 1982).
The DF3 human breast carcinoma-associated 
antigen was prepared against a membrane-enriched 
fraction of a human breast tumour (Kufe et al, 1984). 
It is a member of the polymorphic epithelial mucins and 
is expressed on the apical borders of secretory breast 
epithelial cells (Kufe et al, 1984). It is found in the
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cytosol and on the cell membrane of adenocarcinomas of 
breast, ovary and lung and mesothelial cells (Szpak et 
al, 1984) . Like CK 18 it is not normally expressed by 
haemopoetic and vascular endothelial cells.
Preliminary studies were performed to 
establish the specificity of CK 18 and DF 3 gene 
expression for breast epithelial cells and the 
sensitivity of reverse transcriptase PCR in detecting 
breast epithelial cells in blood.
MATERIALS AND METHODS
The Polymerase Chain Reaction (PCR)
The basic requirements for PCR are oligonucleotide 
primers, the DNA or RNA sequence to be amplified, DNA 
polymerase, various buffers and nucleotides necessary 
for DNA synthesis. The PCR method is based on repeating 
cycles of: denaturation of double-stranded DNA,
annealing of oligonucleotide primers and primer 
extension using DNA polymerase. Denaturation occurs 
when the reaction temperature is raised above 9 0° C. 
In addition, at this temperature the complementary DNA 
strands remain separate in solution. Lowering of the 
reaction temperature to between 55°C and 72°C enables 
annealing of oligonucleotide primers to denatured DNA. 
The primers bind to sequences of DNA flanking the 
portion of DNA to be amplified and because they are 
non-complementary they will not anneal to each other
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but only to opposite DNA strands. The formation of 
primer-DNA complexes as opposed to re-annealing of the 
native DNA strands is enhanced by a vast excess of 
primer in the reaction mixture. The final step of 
primer extension is accomplished by using Tag DNA 
Polymerase to bind to the primer DNA complex and 
synthesise a complementary DNA strand in the 51 to 3 ' 
direction. This enzyme, purified from Thermus 
Aquaticus, is thermostable up to 98°C and therefore 
will not degrade at high denaturation temperatures. 
Furthermore, the use of Tag Polymerase enables the 
annealing temperature to be raised, thereby increasing 
the binding of the primer to the desired DNA sequence 
and reducing non-specific binding to DNA outside the 
region of interest. In other words, the higher the 
temperature the more specific the binding will be 
between the primer and its intended DNA "match".
In each cycle there is a doubling of the DNA 
product such that in a typical PCR analysis of 20-40 
cycles of amplification there will be a million-fold 
amplification of the desired gene product.
Design of Oligonucleotide Primers
Primers were devised from the published gene sequences 
for human cytokeratin 18 (CK 18) (Kulesh and Oshima, 
1988) and the 5' region of the human DF3 antigen (Abe 
et al, 1989) (Figure 17). Each primer consisted of 20 
bases with an average Guanine + Cytosine content of 
about 50% in order to create a similar annealing
FIG 17 a
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Primer Base Sequence
CK 1 - 5’ AG ACC ATGC AAAGCCT G AAC 3' 
CK 2 - 5’ GAAGATCTGAGCCCTCAGGT 3' 
CK 3 - 5* T CTT ACCTGG AC AG AGT GAG 3'
DK 3 1 - 5' C AC AGTGCTT AC AGCT ACC A 3' 
DF 32 - 5' AGGTGGCAGCTGAACCTGAA 3' 
DF 33 - 5* GTTCAGTGCCCAGCTCTACT 3'
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temperature between 55 and 80°C. The possibility of 
mispriming was reduced by avoiding stretches of 
polypurines, polypyrimidines and palindromic sequences. 
In addition, complementarity was avoided at the 3' ends 
of primer pairs to prevent the formation of primer- 
dimer artifacts which could reduce the yield of desired 
product.
In order to prevent amplification of genomic 
DNA, one of the pair of primers for both genes was 
designed to hybridise to cDNA across an intron site. 
This ensured that the primer would only recognise and 
amplify the gene if it was being expressed by 
transcription into RNA. The size of the DNA fragment 
defined by these primers was 17 9 base pairs for CK 18 
and 263 for DF3. A third primer (probe) complementary 
to the central portion of the PCR product was utilized 
for Southern Hybridization.
Analysis of PCR product by gel electrophoresis 
Electrophoresis through agarose gels enables the 
separation and identification of DNA fragments. The 
location of DNA within the gel can be determined 
directly by staining with low concentrations of the 
fluorescent intercalating dye ethidium bromide; bands 
containing as little as 1-10 ng of DNA can be detected 
by direct examination of the gel in ultraviolet light. 
Agarose gels are usually run in a horizontal direction 
and when an electric field is applied across the gel, 
DNA, which is negatively charged at neutral pH,
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migrates towards the anode. The rate of migration is 
determined by a number of parameters including the 
agarose concentration, molecular size of the DNA, 
confirmation of the DNA, composition of the 
electrophoresis buffer and the applied voltage. DNA 
from 200 base pairs to approximately 50 kilobases in 
length can be separated on agarose gels of various 
concentrations. For the purpose of these experiments 2% 
agarose gels were used in Tris-borate (TBE) buffer and 
run at 5 volts/cm. Photographs of gels were made using 
transmitted ultraviolet light (wavelength 3 02 nm) with 
Polaroid Type 57 film.
Analysis of PCR Product by Southern Hybridization 
This transfer technique was first described by Southern 
(1975) and enables the specificity of the PCR product 
to be confirmed. The DNA on the agarose gel is 
denatured in situ and transferred by capillary transfer 
from the gel to a solid support (usually a 
nitrocellulose filter or nylon membrane). The relative 
positions of the DNA fragments are maintained during 
their transfer to the filter. The DNA attached to the 
filter is hybridized to a radiolabelled oligonucleotide 
probe and autoradiography is used to locate the 
positions of bands complementary to the probe.
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PRELIMINARY EXPERIMENTS
Experiment 1 A comparison of CK 18 and DF 3 gene 
expression in primary breast carcinomas and peripheral 
b l o o d .
1.1 RNAzol™ B Extraction of RNA
In order to extract RNA from blood, peripheral blood 
leucocytes were prepared by erythocyte lysis of blood 
obtained from healthy volunteers (see Chapter 5, 
materials and methods). Leucocyte suspensions were then 
sedimented and homogenised with RNAzol™ B solution 
(0.2 ml/106 cells) by repeat pipetting. To extract RNA 
from primary tumour samples, the tissue was first 
frozen at -7 0°C and ground to a fine powder before the 
addition of RNAzol™ B. Chloroform was added (0.2 ml/ml 
lysate) to the prepared samples which were vortexed 
briefly before being chilled on ice for 5 minutes. 
Samples were spun at 12 000 g for 15 minutes at 4°C. 
After centrifugation, the RNA in the aqueous phase (DNA 
and proteins in the interphase and phenol phase) was 
transferred to sterile tubes and precipitated with an 
equal volume of isopropanol for 15 minutes at 4°C. 
Samples were then centrifuged for 15 minutes at 12 000 
g (4°C). The supernatant was removed and the RNA pellet 
washed once with 0.8 ml of 75% ethanol by vortexing 
followed by centrifugation for 8 minutes at 7500 g 
(4°C). The purified RNA pellet was dried briefly under 
vacuum for 10-15 minutes and then dissolved in 50 ul of
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water. A small volume was removed for 
spectrophotometric assessment of the concentration. An 
optical density of 1, at a wavelength of 260 nm, 
represented an RNA concentration of 40 ug/ml. (To 
prevent degradation of RNA, water and all containers 
were autoclaved and treated with diethyl pyrocarbonate 
(DEPC) to remove Ribonuclease and gloves were worn at 
all times to avoid contamination with skin RNase).
1.2 First-Strand cDNA synthesis and PCR Amplification 
of cDNA Product
Reverse transcription of RNA and PCR amplification of 
cDNA was performed in a single reaction tube using a 
combined RNA PCR kit (GeneAmp RNA PCR Kit, Perkin-Elmer 
Cetus, Norwalk, Connecticut, USA) . Contaminating DNA 
was first removed prior to reverse transcriptase PCR by 
adding 10 IU of RNase-free DNase to each sample and
incubating at 37°C for 30 minutes. The reaction was 
then stopped by heating to 95°C for 5 minutes and then 
cooled to room temperature.
1.2.1 Reverse Transcription Protocol
For reverse transcription, lug of RNA (1 ul) was added 
to 19 ul of a reaction mixture (total volume 2 0ul) 
giving final concentrations of: I X  PCR buffer (10
mmol/1 Tris-HCl, pH 8.3, 50 mmol/1 KC1), 5 mmol/1
magnesium chloride, 1 mmol/I each of dATP, dTTP, dGTP
and dCTP, 1 unit RNase Inhibitor, 2.5 units maloney 
murine leukaemia virus reverse transcriptase and 3 0
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pmol "downstream" primer. Each sample was overlaid with 
50 ul mineral oil, heated to 42°C for 15 minutes, 99°C 
for 5 minutes and soaked at 5°C for 5 minutes.
1.2.2 PCR Protocol
For amplification, each reverse transcription reaction 
sample was diluted with 7 9 ul of a PCR mixture 
containing final concentrations of: I X  PCR buffer,
magnesium chloride 2 mmol/1 and 2.5 units AmpliTaq DNA 
Polymerase. 3 0 pmols of "upstream primer" were 
dispensed into each sample to give a total volume of 
100 ul. The PCR reaction consisted of an initial cycle 
of denaturation at 93°C for 5 minutes, primer annealing 
at 55°C for 5 minutes and polymerisation at 73°C for 15 
minutes. 30 PCR cycles were carried out ( 93°C for 1 
minute, 55°C for 1 minute and 73°C for 5 minutes) and 
completed by extension at 73°C for 15 minutes.
1.3 Gel Electrophoresis of PCR Product
1/10 of the PCR product was used for analysis on a 2% 
agarose gel impregnated with ethidium bromide 
(0.5ug/ml) . The gel was run at a voltage of 5 volts/cm 
for approximately 2-3 hours. A DNA ladder suitable for 
sizing double-stranded DNA from 72 to 1353 base pairs 
(PHI X 174 RF DNA/Hae III Fragments, Gibco Brl) was 
used for comparison. The gel was then photographed 
under ultraviolet illumination using a Polaroid camera.
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RESULTS (Figure 18a)
The expected size of the amplified fragment for CK 18 
was 17 9 bp in size. All RNA samples derived from 
peripheral blood of healthy volunteers and from primary 
breast carcinomas gave a band of identical size. 
Comparison with the DNA ladder indicated that this DNA 
fragment was slightly smaller than 194 base pairs in 
keeping with the size of the expected PCR product. The 
expected size of the amplified fragment for DF 3 was 
263 bp in size. Amplification of RNA from all primary 
tumour samples but not from peripheral blood samples of 
healthy volunteers gave a band of the expected size.
These results suggest that while the CK 18 gene is 
expressed in both normal peripheral blood and primary 
breast carcinomas, the DF 3 gene is only expressed by 
primary breast carcinomas. Confirmation of these 
findings was performed by Southern hybridization.
Experiment 2 Southern hybridization of gene products
2.1 Capillary transfer of DNA to nitrocellulose filter 
DNA was first denatured by soaking the gel for 30 
minutes in 0. 5M NaOH and 1. 5M NaCl with constant, 
gentle agitation (x 2), followed by a second gel soak 
for 30 minutes in 1M Tris HC1 (pH 7.5) and 1.5M NaCl (x 
2). Denatured DNA was transferred to a nitrocellulose 
filter (Hybond N+, Amersham, UK) by capillary transfer 
using a standard protocol (Maniatis et al, 1989).
Figure 18 a 16
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2.2 Hybridization of radiolabelled probes to 
immobilized DNA
One hundred nanograms of each oligonucleotide probe was 
radiolabelled by addition of 2 ul lOx Kinase buffer, 2 
ul DTT, 32P - ATP and T4 polynucleotide kinase and
incubated at 37°C for 30 minutes. The radiolabelled 
probe was precipitated with 1 ul transfer RNA (2mg/ml), 
1 ul 0. 2M EDTA (pH 8), 10 ul 7.5M ammonium acetate and 
9 0 ul ethanol on dry ice for 2 hours. Samples were 
centrifuged for 15 minutes at 12 000 g (4°C) and
resuspended in 100 ul of water. Each radiolabelled 
probe was added to 10 ml of hybridization buffer (7% 
SDS/0.5M NaP04, pH 7.4) and sealed in a plastic bag 
with the appropriate filter. Hybridization was 
performed at 42°C for 12 hours. Filters were washed in 
2x SSC/0.1% SDS at room temperature for 30 minutes 
followed by 0. lx SSC/0.1% SDS at 42° C for 30 minutes 
and resealed in plastic bags. Each filter was exposed 
to x-ray film (Kodak XAR-2 or equivalent) at -7 0°C for 
12-24 hours to detect DNA fragments.
RESULTS (Figure 18b)
For CK 18, autoradiography demonstrated a region of 
localised radiodensity over the site of the 
amplification product in all samples. This confirmed 
the PCR product to be the CK 18 gene fragment showing 
that all primary breast carcinomas and peripheral blood 
samples of healthy volunteers expressed the CK 18 gene. 
For DF3, a hot spot coincided with the PCR product in
Figure18b 16
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all primary tumour samples confirming this to be the 
DF3 gene fragment. There was no evidence of DF3 gene 
expression in peripheral blood samples of healthy 
volunteers.
The unexpected presence of the CK 18 gene in 
normal peripheral blood therefore made it unsuitable as 
a marker for breast epithelial cells in blood. In 
contrast, the absence of the DF 3 gene in normal 
peripheral blood in combination with its universal 
expression in primary breast carcinomas made it a 
suitable marker of circulating breast epithelium.
Experiment 3 Sensitivity assay for reverse 
transcriptase PCR using the DF3 gene
A suspension of MCF 7 tumour cells was serially diluted 
in PBS and 0, 10, 102, 103, 104, 105 and 106 cells added 
to 5 ml samples of blood. Erythrocyte lysis, RNA 
extraction, cDNA synthesis and PCR amplification were 
performed as described previously. Analysis of PCR 
products required gel electrophoresis on a 2% agarose 
gel followed by Southern hybridization using a 
complementary radiolabelled probe. A negative control 
of blood RNA and a positive control of MCF 7 RNA were 
also included.
RESULTS (Figure 19)
Electrophoretic analysis demonstrated DF 3 gene 
expression in blood spiked with MCF 7 tumour cells from
Figure 19
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a concentration of 106 to 103 cells/5mls of blood. 
Hybridization with the radiolabelled probe confirmed 
DF 3 gene expression in spiked blood samples and 
demonstrated that the intensity of the signal was 
proportional to the number of tumour cells per blood 
sample. The sensitivity of autoradiographic analysis 
was sufficient to detect DF 3 gene expression in blood 
containing MCF 7 tumour cells at a concentration as low 
as 10 tumour cells/5ml of blood.
In summary, these preliminary in vitro studies 
have demonstrated that reverse transcription PCR is a 
suitable technique for the detection of malignant 
breast epithelium in blood. Amplification for the DF 3 
breast carcinoma-associated gene is specific for breast 
epithelium since haemopoetic and vascular endothelial 
cells do not express the gene. Southern hybridization 
and autoradiography enhance sensitivity thereby 
enabling the detection of very small numbers of 
circulating tumour cells.
Having established optimal experimental 
conditions for the DF3 antigen, reverse transciption 
PCR was then applied to blood samples collected from 
patients undergoing surgery for breast cancer. The aim 
of this study was to investigate whether operative 
manipulation enhanced tumour cell dissemination via the 
bloodstream.
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PATIENT STUDY
Patients undergoing surgery for breast disease were 
recruited into this study. These were 9 patients with 
primary operable breast cancer and 3 with benign breast 
disease. Clinical details are summarised in Table 8. 
Pre-operative assessment of patients with breast cancer 
by chest x-ray, liver ultrasound and bone scan excluded 
those with distant metastases. Approval for this study 
was granted by the Western Infirmary Ethical Committee.
Five ml peripheral blood samples were obtained 
24 hours pre-operatively, intra-operatively and 24 
hours post-operatively. Operative samples were taken at 
the time of maximum surgical manipulation as previously 
described (Chapter 5) . All blood samples were obtained 
by Vacuutainer puncture and the first 5 mis were 
discarded to prevent sample contamination from skin. A 
5 ml blood sample obtained from a healthy female 
volunteer and spiked with 106 MCF7 tumour cells served 
as a positive control. Samples were treated with 
erythrocyte lysis solution and the residual cell pellet 
was stored at - 7 0°C. RNA was extracted by the RNAzol™ 
B technique (0.5 ml RNAzol™ B/5 ml blood) and 1 ug 
used for reverse transcription PCR using the RNA/PCR 
kit and DF 3 primers.
PCR products were analysed by electrophoresis on 2% 
agarose gels with ethidium bromide staining and 
Southern hybridization.
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Table 8
Clinical and Histological Status of Patients 
in RT-PCR Study
Lane
No.
Name Age Size of 
Lesion
Histology Nodal
Status
Operation
2 FH 56 / Fibrocystic / Excision
Biopsy
3 ER 51 / Fibrocystic / Excision
Biopsy
4 JM 45 / Fibrocystic / Excision
Biopsy
5 LH 71 7cm Grade III
Ductal Carcinoma
+ve Mastectomy
6 AY 68 2cm Grade II
Ductal Carcinoma
-ve Lumpectomy
7 MB 57 2cm Grade I
Ductal Carcinoma
-ve Lumpectomy
8 MM 53 5cm Grade III
Ductal Carcinoma
+ve Mastectomy
9 HB 65 2cm Grade III
Ductal Carcinoma
+ve Mastectomy
10 MM 58 8mm Grade I
Ductal Carcinoma
+ve Lumpectomy
11 MJ 69 2cm Grade II
Ductal Carcinoma
+ve Lumpectomy
12 MM 77 7cm Grade III
Ductal Carcinoma
-ve Mastectomy
13 MM 43 1cm Grade I
Ductal Carcinoma
-ve Lumpectomy
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RESULTS
1 Pre-operative (Figure 20a)
Electrophoretic analysis demonstrated expression of the 
DF3 gene in the blood sample of the positive control
(Lane 1) and in the peripheral blood sample of one
patient with primary breast carcinoma (Lane 5) . 
Southern hybridization and autoradiography confirmed 
the presence of the DF3 gene in the peripheral blood 
sample of one patient with breast cancer and its 
absence in all peripheral blood samples of all three 
patients with benign breast disease.
2 Operative (Figure 20b)
In addition to DF3 expression in the peripheral blood 
sample of the positive control (Lane 1), 
electrophoretic analysis demonstrated the DF3 gene in 
the peripheral blood samples of four patients with 
primary breast carcinoma (Lanes 5, 6, 9 and 11).
Southern hybridization and autoradiography further
confirmed DF3 expression in the peripheral blood of
four patients with breast cancer and its absence in the 
peripheral blood of all patients with benign breast 
disease.
3 Post-operative (Figure 20c)
Electrophoretic and autoradiographic analysis failed to 
demonstrate DF3 gene expression 24 hours post- 
operatively in the peripheral blood of any patient who
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had undergone surgery for either benign or malignant 
breast disease.
DISCUSSION
PCR is a highly sensitive molecular biological 
technique which is ideally suited to the detection of 
relatively small numbers of tumour cells in peripheral 
blood. The specificity is primarily dependent upon the 
identification of a gene solely expressed by the cell 
population of interest. At present no genes specific to 
breast cancer have been identified. Therefore, genes 
which are expressed by breast epithelium but not by the 
cellular elements of blood or vascular endothelium were 
targeted. The identification of the gene encoding CK 18 
in normal peripheral blood was therefore totally 
unexpected. In the absence of circulating epithelial 
cells these false positive signals were thought to 
represent sample contamination. Skin is the most likely 
source of such contamination as it is theoretically 
possible to introduce a plug of epithelial cells from 
skin into blood during venesection. However, this risk 
was minimised by discarding the first 5 mis of blood 
during collection. In addition immunocytochemical 
studies indicate that skin does not express CK 18 (Moll 
et al, 1982). This suggests that the presence of the CK 
18 gene in blood may not represent epithelial 
contamination rather such "illegitimate transcription" 
may reflect low levels of CK 18 mRNA transcription in
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non-epithelial tissues (Chelly et al, 1989), the 
products of which may not be detectable by conventional 
immunocytochemical techniques. Evidence of keratin gene 
expression in cells of haemopoetic origin using PCR has 
recently been confirmed not only for cytokeratin 18 but 
also for cytokeratin 8 (Traweek et al, 1993).
DF3 antigen was expressed in breast 
epithelium, but in contrast to CK 18 it was absent in 
normal peripheral blood. The epithelial-specific nature 
of DF3 therefore made it a suitable target for the 
detection of breast epithelium in blood. The level of 
gene expression was sufficient to enable malignant 
breast epithelial cells to be identified at a 
concentration as low as 10 tumour cells per 5 mis of 
blood. The universal expression of DF3 in benign and 
malignant breast tissue is in contrast to conventional 
immunocytology where the level of expression is 
significantly lower in benign tissue (Kufe et al, 
1984) . This may reflect the ability of PCR to detect 
low levels of DF3 expression in benign breast tissue 
not detectable by conventional immunocytological 
methods.
Having established optimal conditions for 
reverse transcription PCR, a preliminary study of 
patients with breast cancer was performed to determine 
whether surgery promoted haematogenous tumour cell 
dissemination. DF3 gene expression was identified in 
the peripheral blood of 1 of 9 patients pre- 
operatively, 4 of 9 patients intra-operatively and in
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none of the patients 24 hours post-operatively. None of 
the patients with benign breast disease demonstrated 
DF3 expression in the peripheral blood. The presence of 
the DF3 antigen in the blood of patients undergoing 
surgery for malignant disease suggested that it was due 
to the presence of circulating malignant epithelial 
cells. The presence of malignant cells in the 
bloodstream of one patient pre-operatively would 
suggest that spontaneous haematogenous shedding from 
primary does occur while the presence of malignant 
cells in four patients during surgery suggests that 
operative manipulation enhances tumour cell 
dissemination. The absence of tumour cells in the
bloodstream 24 hours folowing surgery confirms previous 
experimental studies by Fidler (197 0) which 
demonstrated rapid destruction of circulating tumour 
cells. In view of the size of the study it was not
possible to identify any valid associations between the 
presence of circulating tumour cells and patient 
clinico-pathological prognostic data.
This preliminary study suggests that 
operative manipulation of malignant breast neoplasms 
may promote tumour cell dissemination via the 
bloodstream. Quantification of tumour cells was not
performed as reverse transcription PCR is not primarily 
designed for this type of analysis, rather it is used 
as a rapid method for the detection of mRNA at low
concentrations as required for the detection of a minor 
subpopulation of tumour cells in blood. However,
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future studies should attempt to incorporate 
quantification techniques as this will determine 
whether the degree of tumour cell shedding is related 
to prognosis and variables such as type of operation, 
stage of disease and grade of malignancy. The 
identification of patients at risk from haematogenous 
dissemination may alter the management of patients with 
malignant disease.
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FINAL DISCUSSION
The introduction documented considerable evidence 
indicating an association between the coagulation 
system and the intravascular phase of the metastatic 
process. Microscopy studies in animal models have
demonstrated that circulating tumour cells arrest in 
the microcirculation of target organs surrounded by a 
meshwork of fibrin and platelets. This is thought to 
enhance metastasis by facilitating adhesion of tumour 
cells to vascular endothelium thereby stabilizing
tumour cell arrest in the microvasculature. Studies 
using a rat model of "artificial metastasis" have 
demonstrated inhibition of metastasis following the 
administration of coumarin anticoagulants and more 
recently following the administration of the 
fibrinolytic agent Streptokinase. Such therapy might 
therefore form the basis of an effective antimetastatic 
treatment if administered to patients at risk from 
haematogenous dissemination from primary tumours. 
Animal studies have demonstrated that manipulation of 
primary tumours facilitates tumour cell dissemination 
via the bloodstream and may promote metastasis. The 
"no-touch" isolation technique of Turnbull (1967)
suggests that surgical manipulation of tumours may 
enhance the metastatic process by promoting intra­
operative haematogenous tumour cell dissemination.
This technique has largely been abandoned because of 
poor reproducibility, but the theory underlying it has
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not been entirely refuted. Peri-operative
antimetastatic treatment using fibrinolytic therapy 
might therefore have a role in preventing metastatic 
progression in patients with cancer.
The work in this thesis was divided into two 
closely related investigations. The first half of this 
thesis was designed to investigate the hypothesis that 
the antitumour effect of Streptokinase was secondary to 
dissolution of the fibrin clot surrounding tumour cells 
arrested in the microcirculation. A rat model of 
metastasising breast carcinoma was therefore used to 
study the mechanism of Streptokinase-mediated tumour 
inhibition. The second half of this thesis was 
designed to investigate whether operative manipulation 
of malignant tumours facilitates tumour cell 
dissemination via the bloodstream. A clinical study of 
patients with operable breast cancer was therefore 
performed and peri-operative blood samples analysed for 
the presence of tumour cells using immunocytochemical 
and molecular biological techniques.
The initial aim of these studies was to 
validate the animal model of "artificial metastasis" 
and confirm that Streptokinase inhibits pulmonary 
tumour seeding in this animal model. The results of 
these preliminary studies validated the results of 
previous work by confirming the dose and time of 
administration of Streptokinase that significantly 
inhibits pulmonary tumour seeding in this animal model. 
However, the mechanism of tumour inhibition remained
178
unclear as conclusive evidence of an association 
between fibrin and tumour cells within the 
microvasculature had not been proven in this model. In 
the absence of histological evidence of intravascular 
fibrin clot lysis, it was therefore possible that 
Streptokinase caused this effect of tumour inhibition 
via a completely different mechanism. The working 
hypothesis at this stage was that Streptokinase 
inhibited pulmonary tumour seeding by destroying fibrin 
clot surrounding tumour cells trapped in the pulmonary 
microcirculation.
To test this hypothesis, it was important to answer the 
following question:
Is the effect of Streptokinase in this animal tumour 
model associated with fibrin clot lysis?
The study designed to answer this question was to 
assess Plasma Fibrin Degradation Products (FDP), a 
highly sensitive indicator of fibrinolysis detected by 
a latex agglutination reaction. Analysis of rat plasma 
FDP demonstrated that there was a tendency towards 
increased fibrin clot lysis in animals receiving 
Streptokinase when compared with controls although this 
failed to reach statistical significance. The 
demonstrable rise in FDP in the untreated control 
group was thought to be due to spontaneous activation 
of the fibrinolytic system in this group, a phenomenon 
previously recognised in rodents, in combination with 
activation resulting from traumatic cardiac puncture 
and the stress of anaesthesia.
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In an attempt to provide further evidence of 
fibrin clot lysis, the effect of another fibrinolytic 
agent on pulmonary tumour seeding was studied. Human 
recombinant tissue plasminogen activator (rt-PA) is 
different to Streptokinase in relation to both 
structure and mechanism of action. The results of this 
study demonstrated that rt-PA was as effective as 
Streptokinase in inhibiting pulmonary tumour seeding. 
The demonstration that two pharmacologically unrelated 
fibrinolytic agents had a similar antitumour effect 
suggested that this effect was probably secondary to 
fibrin clot lysis.
These two studies have provided mutually 
supportive findings as to the mechanism of inhibition 
of "artificial metastasis" by Streptokinase. While such 
independent confirmation makes it likely that this 
effect of Streptokinase is secondary to fibrin clot 
lysis, microscopic evidence for intravascular
dissolution of thrombus has not been demonstrated. This 
would require extensive microscopic studies of changes 
in the pulmonary microvasculature under the 
experimental conditions described earlier. The overall 
view of the evidence presented makes it likely that the 
antitumour effect of Streptokinase and rt-PA is related 
to the fibrinolytic properties of these agents.
Platelets are also an important component of 
thrombi surrounding tumour cells arrested in the 
microvasculature. If fibrin clot formation and platelet 
deposition are required to facilitate increased tumour
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cell entrapment, then their destruction should
theoretically have an additive inhibitory effect. A 
further study was therefore performed to answer the 
following question:
Is the inhibition of pulmonary tumour seeding by 
Streptokinase potentiated by antiplatelet therapy?
Since tumour cell-induced platelet activation 
may occur via a number of pathways including the
generation of thrombin and activation by ADP, this 
study used two antiplatelet agents with separate 
mechanisms of action. Although there was a trend
towards a reduction in pulmonary tumour seeding with 
aspirin this failed to reach a significant level
suggesting that platelet activation by the Mtln3 cell 
line may be independent of the cyclo-oxygenase pathway. 
In contrast, ticlopidine significantly inhibited 
pulmonary tumour seeding suggesting that tumour cell- 
induced platelet aggregation by the Mtln3 cell line may 
be dependent on the generation of ADP. The combination 
of ticlopidine and Streptokinase was no more effective 
than Streptokinase treatment alone indicating that 
tumour cell-platelet interactions may be less important 
than fibrin deposition in the metastatic process.
It is important to stress that there are 
limitations of artificial, intravenous models of 
metastasis and that the metastatic behaviour of a bolus 
injection of a cloned tumour cell line may not 
necessarily reflect spontaneous metastasis from a 
heterogeneous primary tumour population. However, this
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model was simply designed to enable investigation of 
the intravascular phase of the metastatic process. 
Further studies are required to investigate whether 
Streptokinase and rt-PA have a similar effect on the 
spontaneous metastatic potential of established 
tumours.
The demonstration that fibrinolytic agents 
inhibit metastasis raised further questions with regard 
to the clinical role of such agents in the management 
of patients with cancer. The introductory section 
documented evidence to suggest that
anticoagulant/fibrinolytic therapy might be beneficial 
although the results have been compromised by a 
preponderance of patients with advanced disease in whom 
the benefits of antimetastatic therapy would be 
minimal. To be effective it is clear that such 
treatment should be applied to patients with early 
cancer but at risk from haematogenous dissemination.
Studies based on animal models indicate that 
surgical manipulation of malignant tumours promotes 
tumour cell shedding into the circulation. In addition, 
surgical stress enhances tumour survival in the 
bloodstream by inducing a state of relative immune 
suppression while activation of coagulation encourages 
tumour cell entrapment in the microcirculation by 
promoting a fertile, hypercoagulable "soil". If tumour 
cells that are shed at the time of surgery are 
prevented from adhering to vascular endothelium and are 
maintained in circulation, they will eventually die.
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Fibrinolytic agents administered in the perioperative 
period should therefore theoretically prevent tumour 
seeding in the microcirculation thereby reducing 
metastasis. However, fibrinolytic therapy is not 
without risk and in particular allergic reactions to 
Streptokinase and post-operative haemorrhage must be 
considered. While rt-PA avoids the former complication, 
the risk of bleeding, although reduced, still exists. 
Large prospective studies would therefore only be 
justifiable if there was conclusive evidence of intra­
operative tumour cell dissemination.
Our initial attempts to identify tumour cells in 
the bloodstream of breast cancer patients during 
surgery utilized flow cytometry to detect tumour cells 
labelled with fluorochrome-conjugated antibody. Optimal 
antibody labelling of tumour cells was achieved using 
an anticytokeratin antibody MNF 116. However, one 
colour flow cytometric analysis failed to accurately 
identify tumour cells in blood due to incomplete 
separation of cytokeratin labelled-tumour cells and 
highly autofluorescent leucocytes. Two colour flow 
cytometry enhanced tumour cell detection by first 
excluding the majority of leucocytes labelled with a 
panleucocyte antibody. This technique was then applied 
to a pilot clinical study of breast cancer patients 
during surgery but failed to detect peri-operative 
tumour cell shedding. An assessment of sensitivity 
however demonstrated that this technique was unreliable 
to detect tumour cells at low concentrations.
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Therefore, the possibility that tumour cell shedding 
had occured during operative manipulation could not be 
completely excluded using the technique of flow 
cytometry.
Gene amplification by reverse transcriptase PCR 
provided a technique with the necessary sensitivity and 
specificity to detect a minor subpopulation of breast 
epithelial cells in blood. Oligonucleotide primers were 
designed to two genes encoding structural epithelial 
proteins, cytokeratin 18 and the breast carcinoma 
associated antigen DF3. The absence of epithelial cells 
in normal peripheral blood suggested that these genes 
were suitable targets for circulating malignant breast 
epithelium. However, amplification for the
cytokeratin 18 gene demonstrated that it was expressed 
in the blood of healthy volunteers. The strength and 
consistency with which the signal occurred suggested 
that it was unikely to be due to epithelial cell 
contamination, rather it was due to low level
transcription of the CK 18 gene in non-epithelial 
tissues. In contrast, DF 3 expression was consistently 
shown in cells derived from primary malignant breast 
carcinomas but was absent in all normal peripheral 
blood samples. An in vitro assessment of sensitivity
demonstrated that 3 0 cycles of PCR using the DF3 
primers could detect 10 breast carcinoma cells per 5 ml 
of blood. A preliminary clinical study of 9 patients 
undergoing surgery for primary breast carcinomas
demonstrated the presence of cells expressing the DF3
184
gene in the peripheral blood of one patient pre- 
operatively and four patients during surgery. No DF3 
positive cells were identified in post-operative blood 
samples or in any blood samples obtained from patients 
undergoing surgery for benign breast disease. The 
presence of DF3 positive cells in patients undergoing 
surgery for malignant disease but not benign disease 
strongly suggests their malignant origin. Furthermore, 
their presence in the peripheral blood of four of nine 
patients during surgery suggests that surgical 
manipulation of malignant breast tumours may enhance 
haematogenous tumour cell dissemination.
It is important to stress the preliminary nature 
of this study and a larger prospective study is 
required to further confirm these findings. Long term 
follow-up is essential to determine whether peri­
operative tumour cell shedding promotes metastasis 
although interpretation of results may be difficult as 
some patients may have occult metastases at the time of 
surgery. Reverse transcription PCR is an extremely 
sensitive and specific method for the detection of 
small numbers of tumour cells in blood and it is not 
primarily designed for quantitative analysis. Since the 
inefficiency of the the metastatic process determines 
that the ratio of circulating tumours cells to the 
number of eventual metastases is high, future studies 
should incorporate quantitative analysis in order that 
the degree of tumour cell shedding can be correlated to 
prognosis. The identification of patients at risk from
185
haematogenous dissemination during surgery, in 
combination with the development of a suitable 
antimetastatic regime, may significantly alter the 
peri-operative management of patients with malignant 
disease.
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